Renal prostaglandins in experimental renal hypertension and in autoregulation of renal blood flow by Smith, George William
RENAL PROSTAGLANDINS IN EXPERIMENTAL RENAL
HYPERTENSION AND IN AUTOREGULATION OF
RENAL BLOOD FLOW
BY
GEORGE WILLIAM SMITH, BSc (Hons. Edinburgh]
THESIS SUBMITTED FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY, UNIVERSITY OF EDINBURGH, 1977
I hereby declare that this thesis was composed by myself alone and
that it describes work, some of which was performed in collaboration
with various other people, as outlined in the acknowledgements.
ABSTRACT
Accompanying the arterial hypertension in the dog following the partial
constriction of one of a pair of renal arteries, there are rises in
plasma renin activity, plasma volume and renal venous prostaglandins
E and F of the contralateral kidney, reaching maxima on days 2, k and
5 respectively. By the tenth day all parameters were normal, with the
exception of blood pressure. It is suggested that the contralateral
kidney responds to the fluid retention by natriuresis and diuresis
mediated by an increase in prostaglandin synthesis. It is also
concluded that PGE is unlikely to play a role in the antihypertensive
action of this kidney. A transient elevation of circulating PGA was
observed in some experiments.
In the two-kidney Goldblatt rat a transient decrease in renal plasma
flow of the clipped kidney was seen whilst the contralateral kidney
showed no change. Renal venous PC-E2 and PGF2CK concentrations changed
inversely with renal plasma flow and calculated secretion rate of
the clipped kidney fell, although it was not possible to establish the
significance of this fall. Such a fall could lead to a reduction in
intrarenal vasoconstrictor potentiation produced by prostaglandins in
this species. The absence of a rise in secretion rate of PGE2 in either
kidney raises further doubt concerning renal prostaglandins as mediators
of the antihypertensive action of the kidney in the rat.
In the pump-perfused dog kidney calculated secretion rate of PGE fell
as perfusion pressure fell below the autoregulation range, whilst PGF
secretion did not change. Meclofenamate failed to abolish renal blood
flow autoregulation, despite a "J0% fall in prostaglandin synthesis and it
is therefore concluded that autoregulation is not dependent on prostaglandins.
GLOSSARY OF ABBREVIATIONS
ang angiotensin
ADH antidiuretic hormone (vasopressin)
BP blood pressure
CVP central venous pressure
ECFV extracellular fluid volume






IFV interstitial fluid volume
i.v.p. intravenous pyelogram
OD optical density
PAH para amino hippuric acid
PG prostaglandin - followed by letter denoting type, e.g.
PGA, PGB etc.
PRA plasma renin activity
PV plasma volume
RAP renal artery (perfusion) pressure
RIA radioimmunoassay
RICs renal interstitial cells
RBF renal blood flow
SHR spontaneously hypertensive rats
"One-Kidney Goldblatt" preparations will be the term used to describe
hypertensive animals in which the Kidney contralateral to the Kidney
with the renal artery clamp has been removed whilst "two-Kidney
Goldblatt" preparations will describe animals in which the contra¬
lateral Kidney is left intact.
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The introduction of a normal kidney into the circulation of dogs
with perinephritic cellophane hypertension (Kolff,1958) and one
kidney Goldblatt hypertensive rats CTobian, Schonning and Seefeldt,
1964) rapidly reduces blood pressure CBP) to normal despite replace¬
ment of the urine loss. The presence of the untouched kidney in
the two kidney Goldblatt dog has been shown to lead to a milder
form of hypertension than if this kidney is removed (Goldblatt,
1937,■ Goldblatt, Kalin and Hanzal, 1939) and this has been interpreted
as a protective mechanism of the kidney (Fascioli,1938).
An endocrine antihypertensive action has been implicated since even
in the absence of excretion by such maneouvres as bilateral uretero-
caval anastomosis, an antihypertensive effect is still seen in the
dog (Grollman, Muirhead and Vanatta, 1949).
Muirhead's group has drawn attention to the renal medulla. In the
renoprival hypertensive dog (bilateral nephrectomised), auto-
explanation of whole kidney and medulla but not of the cortex, prevent
hypertension from developing (Nuirhead, Jones and Stirman, 1960). In
the renoprival hypertensive rat, rabbit medullary extract is anti¬
hypertensive but it is without effect on normal rats (Nuirhead,
Leach, Daniels and Hinman, 1968a). Protection against malignant
hypertension in rabbits with subcutaneous renal medulla implants only
lasts as long as the implants are left in position and electron
micrographs show hyperplasia of the renal interstitial cells (RICs)
in close proximity to the capillaries (Nuirhead, Brooks, Pitcock
and Stephenson, 1972).
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Working independently of Muirhead, Lee's group identified vasodepressor
lipids CVDL3 in the rabbit medulla (Lee, Hickler, Saravis and Thorn,
1963] with PGE^ accounting for the greatest activity (Daniels, Hinman,
Leach and Muirhead, 19673.
The Renal Prostaglandins
Prostaglandins have been identified in the renal medullae of all
species so far studied including dog (Crowsh.aw, McGiff, Strand,
Lonigro and Terragno, 19703, rat (Somova, 19713, rabbit (Crowshaw,
19713 and man (Vance, Attallah, Prezyna and Lee, 19733, with the
highest concentrations in the medulla, the major site of the
synthetizing enzyme, whilst the lowest levels are in the cortex, the
O |t
site of the degrading enzymes (Anggard, Larsson and Samuelsson, 1971;
o I,
Larsson and Anggard, 19733. Prostaglandins are believed to be released
on synthesis and are not stored in most organs, including the kidney
(McGiff and Nasjletti, 19733.
Cultured renal interstitial cells (RIC s3 are rich in granules con¬
taining triglycerides, fatty acids and prostaglandins E^'F^c* and A^
(Muirhead, Germain; Leach, Brooks and Stephenson, 19733. According to
Janzen and Nugteren (19713 the collecting duct cells provide an even
richer source of prostaglandins.
Renal Prostaglandin Synthesis
The common substrate for PGE^ and PGF^ synthesis is 5,8,11,14
eicosatetranoic acid (arachidonic acid3, which is released from
phospholipids by acyl hydrolase enzymes such as phospholipase A.
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Free arachidonic acid is converted to PGE^ and PGF2<* via the common
endoperoxide intermediatesPGG^ and PGf^. Non-steroidal anti¬
inflammatory drugs such as aspirin, indomethacin and meclofenamate
prevent the formation of the endoperoxides (see Flower, 1974).
There is great controversy as to whether PGA exists naturally or is
a dehydration product of PGE formed on extraction. Combined gas
liquid chromatography-mass spectrometry has failed to detect PGA in
human blood (Frolich, Sweetman, Carr, Hollifield and Oates, 1975),
rabbit renal venous blood (Davis and Horton, 1972), rabbit kidney
° it
(Larsson and Anggard, 197B) and rat kidney (Pugsley, Beilin and
Peto, 1975).
However, radioimmunoassay (ria) techniques have detected PGA-like
material in human and rat blood (Zusman, 1973; Zusman, Spector,
Caldwell, Speroff, Schneider and Nulrow, 1973a; Zusman, Forman,
Caldwell, Speroff and Mulrow, 1973b; Lee, 1973; Lee and Attallah,
1975; Hornych, 1976). Less than 2% conversion of PGE to PGA was
reported by Zusman, Caldwell and Speroff (1972) during extractions.
To date the only definite evidence of an enzyme capable of forming
PGA was reported in human blood and has been named PGA dehydrase
since it enzymatically dehydrates PGE (Polet and Levine, 1975).
Prostaglandin Metabolism
15-hydroxy prostaglandin dehydrogenase and prostaglandin 13,14-
reductase, present in the cortex, maintain a medullary-cortical
O
%t
prostaglandin concentration gradient (Anggard et al, 1971). According
- 4 -
to Aiken and Vane (.1973) over 80% of the PGE^ entering the kidney is
metabolised and the majority of PGA^ is degraded to 13,14 dihydro
PGA^ (Attallah, Duchesne and Lee, 1975).
Circulating PGE^ and PGFare removed almost totally by the lungs
(Ferriera and Vane, 1967) although PGA passes freely (Florton and
Jones, 1969) and this has been verified using ria in dog (Robertson,
1975). The liver is also reported to metabolise PGE (Nakano and
Cole, 1969) and PGA (Horton and Jones, 1969).
Renal Prostaglandin Release
Various stimuli are reported to release renal prostaglandins such as
renal ischaemia (McGiff, Crowshaw, Terragno, Lonigro, Strand,
Williamson, Lee and Ng, 1970a; Herbaczynska-Cedro and Vane, 1973;
Gross, Mujovic, Jubiz and Fisher, 1976), renal sympathetic nerve
stimulation (Davis and Horton, 1972; Dunham and Zimmerman, 1970),
catecholamines (Needleman, Douglas, Jakschuk, Stoeckler and Johnson,
1974; McGiff, Crowshaw, Terragno and Lonigro, 1970b), angiotensin I
and II (McGiff, Crowshaw, Terragno and Lonigro, 1970c; Needleman,
Kauffmann, Douglas, Johnson and Marshall, 1973; Aiken and Vane, 1973)
and bradykinin (McGiff, Terragno, Malik and Lonigro, 1972).
The catecholamine effect has been shown to be due to <* receptor
stimulation (Needleman et al, 1974) and the competitive angiotensin
II antagonist, 8-leu-angiotensin II prevents release due to
angiotensin (Needleman et al, 1973),
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In isolated rabbit medulla slices only ADH had been shown to cause
direct release (Kalisker and Dyer, 1972; Sirvio and Gagnon, 1974)
implying that perhaps the prostaglandin release due to other agents
is a consequence of haemodynamic or excretion changes. Recently,
however, angiotensin has been reported to cause direct release
in rat papillary slices (Danon, Chang, Sweetman, Nies and Oat.es,
1975) and in rabbit papilla (Oates, in personal communication to
Zins, 1975).
Intrarenal Role of Prostaglandins
Prostaglandins affect total renal blood flow (RBF), intrarenal blood
flow distribution and the diuresis and natriuresis mechanisms.
A. Haemodynamics
-1 -1
PGE^ infusion CO.01 - 0.30 jjg kg min ) into the renal artery
of dog increases RBF, whereas PGF^^ is without activity
(Tannenbaum, Splawinski, Dates and Nies, 1975). In addition
II
PGA^ is a weak renal vasodilator CFulgraff and Brandenbusch,
1974). Arachidonic acid elevates RBF in dog and prostaglandin
synthetase inhibitors prevent this (Tannenbaum et al, 1S75).
In the anaesthetised dog, basal RBF is dependent on a continuous
synthesis of prostaglandins, probably of PGE^ (Lonigro, Itskovitz,
Crowshaw and McGiff, 1973), but it is doubtful if there is any
dependence in the conscious dog (Zins, 1975; Kirschenbaum and
Stein, 1976).
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Indomethacin reduces total RBF and cortical blood flow but
increases the outer/inner cortical flow ratio in isolated
canine kidney (Itskovitz, Stemper, Pacholczyk and McGiff,
1973), and reduced medullary flow is reported in rat (Solez,
Fox, Miller and Heptinstall, 1974). Conversely, PGE^ infusion
increases cortical flow with a greater effect on the inner
cortex and arachidonic acid increases only inner cortical
flow (Chang, Splawinski, Oates and Nies, 1975). A similar
finding is reported with arachidonic acid in the rabbit
C jj
(Larsson and Anggard, 1974).
Again in the conscious dog prostaglandin synthetase inhibition
does not alter intrarenal haernodynamics (Zins, 1975;
Kirschenbaum and Stein, 1976), although reduced cortical flow
is reported in the conscious rabbit (Beilin and Bhattacharya,
1975).
There is evidence to suggest that renal reactive hyperaemia
.is mediated by prostaglandins (Herbaczynska-Cedro and Vane,
1974; Owen, Ehrhart, Weidner, Haddy and Scott, 1975; Swain,
Heyndrickx, Boettcher and Vatner, 1975). Renal prostaglandins
were also implicated as mediating RBF autoregulation
(Herbaczynska-Cedro and Vane, 1973) but this has been challenged
and will be discussed later in section 3.
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B. Excretory Effects of Prostaglandins
1) Natriuresis
The appearance of PG-like material in the renal venous blood
after interventions, which lower RBF, is associated with a
return of RBF and urine flow (McGiff et al, 1970a, 1970b;
Herbaczynska-Cedro and Vane, 1974). PGE^ and PGF^01 produce
dose dependent natriuresis in the dog (Fulgraff, Brandenbusch
and Fleintze, 1974; Tannenbaum et al, 1975) although PGF2<* is
much weaker and PGA is also a weak natriuretic agent (Fulgraff
et al, 1974) .
In dog, the natriuresis is accompanied by a fall in urine ■
osmolality due to a rise in free water clearance. Micropuncture
studies suggest that PGE2 inhibits sodium reabsorption in the
distal tubule of rat resulting in natriuresis and a rise in
urine osmolality (Fulgraff and Meiforth, 1971), whereas in dog
PGE^ but not PGE2 inhibits proximal sodium reabsorption
(Strandhoy, Oft, Schneider, Willis, Beck, Davis and Knox, 1974).
Indomethacin results in a decrease in urine and sodium excretion
in anaesthetised dog (Feigen, Klainer, Chaprick and Kadowitz,
1976; Olsen, Magnussen, Eilertsen, 1976) and a similar effect
is reported in the rabbit (Lee and Attallah, 1974).
It is therefore generally accepted that the renal prostaglandins
mediate natriuresis and may be the long sought after "natriuretic
hormone" system. Frusemide is inactive in man (Patak, flookerjee,
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Bentzel, Hysert, Babej and Lee, 1975) and rabbit (Oliw,
1« O V
Kover, Larsson and Anggard, 1976) after indomethacin. There
are, however, converse findings.
In the conscious dog, prostaglandin synthetase inhibition
causes natriuresis, with no change in urine volume flow
(Kirschenbaum and Stein, 1976) in agreement with the findings
in the isolated dog Kidney (Vankerweghem, Ducobu, D'Hollander,
1975) .
Human peripheral plasma (Zusman et al, 1973a; Lee and Attallah,
1974) rat plasma and renal PGA^ concentrations (Zusman et al,
1973b) change inversely with sodium intake as does PGE^ in the
rabbit kidney (Tobian and O'Donnell, 1976). These changes are
the opposite expected of a natriuretic agent but it is possible
that they reflect changes in response to circulating angiotensin.
Blood volume expansion in the rat raises the blood PG-like
activity only if both kidneys are intact (Papanicolou, 1972, 1975)
and urinary prostaglandin excretion is also elevated (Papanicolou,
Mountokalakis, Safar, Sotiropoulou, Bariety and Milliez, 1976).
In support of this, an essential fatty acid deficient diet
(Rosenthal, Simone and Silbergleit, 1974), aspirin (Susie and
Sparks, 1975) and indomethacin, (Dusing, fielder and Kramer,
1976) prevent the excretion of saline loads in rats. However,
arachidonic acid has been reported to hinder saline load
excretion in rats (Weber, Holzgreve, Stephan and Herbst, 1975).
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In the dog, the injection of sodium chloride into the renal
artery causes the release of PGE (Jubiz, Terashima and Anderson,
19761 and acute sodium loading increases the urinary excretion
of PGE (Olsen, Magnussen and Eilertsen, 19761 but little is
Known of the effects of chronic volume loading in this species.
2) Interaction with ADH
There is considerable evidence implicating the renal prostaglandins
as antagonists of the renal actions of ADH. PGE^ inhibits the
cyclic AMP dependent increase in water permeability caused by
ADH in the toad bladder COrloff and Handler, 19651 and in the
rabbit collecting duct (Grantham and Qrloff, 19681. Prostaglandins
elevate the free water clearance in dog (Fulgraff et al, 1974;
Tannenbaum et al 19751 and in man (Lee, McGiff, Kannegiesser,
Mudd, Aykent and Frawley, 1969; Fichman, 1970) but a decrease is
reported in the rat (Fulgraff and Meiforth, 1971).
In the hypophysectomised anaesthetised dog, the antidiuretic
effect of exogenous ADH is potentiated by indomethacin or
meclofenamate pretreatment (Anderson, Berl, McDonald and
Schrier, 1975a), The diuresis seen with clonidine in the dog
is associated with a rise in urine PGE-like activity with no
change in ADH excretion. Both ADH and indomethacin prevent the
clonidine induced diuresis (Dlsen, 1976).
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ADH is one of the few substances which directly releases PGE
from the Kidney (Kalisker and Dyer, 1972; Sirvio and Gagnon,
1974) and in view of the evidence above showing that PGE can
antagonise the action of ADH on the collecting ducts, then
the case for renal prostaglandins acting as physiological
modulators of the ADH antidiuresis is strengthened.
Curiously in the isolated canine kidney, devoid of ADH,
indomethacin increases collecting duct permeability, suggesting
that either indomethacin acts directly on the collecting ducts
or else the renal prostaglandins can act directly on the ducts
to decrease permeability CVankerweghem et al, 1975).
3) Prostaglandins - Renin Interactions
Renal prostaglandins may affect the renin system in several
ways.
a) The intrarenal vasoconstrictor effect of angiotensin II
is antagonised by the renal prostaglandins since inhibition
of prostaglandin synthesis leads to potentiation of the
renal vasoconstriction (Aiken and Vane, 1973; Satoh and
Zimmerman, 1975a). Angiotensin releases renal prosta¬
glandins (McGiff et al, 1970a, 1970b; Needleman et al,
1973; Aiken and Vane, 1973), possibly by a direct
mechanism (Danon et al, 1975). The acute rise in angio¬
tensin concentration during unilateral renal artery
constriction in the dog leads to a reduction in renal
blood flow of the contralateral kidney (Satoh and
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Zimmerman, 1975b) and releases prostaglandins from this
kidney (McGiff et al, 1970a; Pamnani, Simon and Ovenbeck,
1976).
The ischaemic kidney in dog is also reported to release
prostaglandins (McGiff et al, 1970a) and this appears to
be due to the renin released since angiotensin antagonists
prevent the prostaglandin release (Satoh and Zimmerman,
1975a).
b) Early reports conflicted as to how prostaglandins affect
renin release probably due to the use of infusions, which
may not mimic the effects of endogenous release (see
o
Larsson, Weber and Anggard, 1974).
In the rabbit sub-hypotensive doses of arachidonic acid
elevate and indomethacin lowers PRA (Larsson et al, 1974).
Indomethacin produces a similar effect in volume loaded
rats (Weber et al, 1975). The rise in PRA after bilateral
renal artery stenosis in the rabbit, is prevented by
O ii
indomethacin (Anggard, Larsson and Weber, 1976). In man
PRA is decreased by indomethacin (Rumpf, Frenzel, Lowitz
and Scheler, 1975) whilst PGA^ does not affect PRA but
causes direct release of aldosterone (Fichman and Horton,
1973). .
c) PGA^ and A^ but not the E series are competitive inhibitors
of human renin (Kctcher and Miller, 1974), which may be of
relevance in vivo, since bilateral nephrectomy in rats has
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been shown to remove an inhibitory influence upon the renin
Kinetics (Romero, Lazar, Elkins and Hoobler, 1969). In the
two-kidney Goldblatt rabbit, removal of the untouched kidney
also removes the renin inhibitory factor (Lazar, Romero
and Hoobler, 1971). The hypertension in dog, during the
first two hours after clamping has been shown to be renin-
dependent and the hypertension is milder in the two-kidney
Goldblatt dog than in the one-kidney preparation, for a
given PRA (Bianchi, Baldoli, Lucca and Barbin, 1972).
These studies suggest the presence of a renal renin inhibitor,
not necessarily a prostaglandin, but possibly the lysophos-
pholipid described by Sen, Smeby and Bumpus (1968). Osmond
(1972) reported an elevation of this inhibitor in the
contralateral kidney of the two-kidney Goldblatt rat.
Whilst a renin preinhibitor may play a role in the control
of BP it cannot explain the antihypertensive effect of renal
medulla in anephric animals (Huirhead et al, 1960) or in
the later stages of hypertension when renin levels are
normal (see discussion of section 1).
Prostaglandin - Sympathetic Interactions
Prostaglandins modulate adrenergic activity by acting at pre- and post¬
junctional sites of the adrenergic nerve. PGE^ and arachidonic acid
decrease noradrenaline overflow from the rabbit kidney during nerve
stimulation (Frame and Hedqvist, 1975). PGE^, E^ and attenuate
the vasoconstriction caused by nerve stimulation in the rabbit kidney
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but do not affect the response to noradrenaline and PFG7<* potentiates
v both stimuli (Malik and McGiff, 1975), A similar response is reported
in the dog kidney, with the exception that the noradrenaline response
is also slightly attenuated (McGiff et al, 1970b). As noradrenaline
(Needleman et al, 1974; McGiff et al, 1970b) and renal nerve stimulation
(Dunham and Zimmerman, 1970; Davis and Horton, 1972) both release
renal prostaglandins, then it is proposed that the renal prostaglandins
may act as modulators of intrarenal sympathetic activity.
Curiously in the rat kidney, arachidonic acid, PGE, PGE^ and PGA2
potentiate nerve stimulation and noradrenaline and at higher doses
cause direct vasoconstriction (Malik and McGiff, 1975).
Extra-renal Effects of Prostaglandins
In dog PGE and PGA are vasodilators, A being more active by the
intravenous route although less active intra-arterially due to the
pulmonary degradation of PGE (Horton and Jones, 1969). These
prostaglandins also dilate dog hind limb capacitance vessels (Conway
and Hatton, 1975) as does PGC2 (Jones, Kane and Ungar, 1974) and
is in fact more active than either PGA2 or PGE2 (unpublished
observations, 1973).
In the dog and rat, PGF2<* is a pressor agent due to venoconstriction
and elevation of the cardiac output (Ducharme, Weeks and Montgomery,
1968). PGF^ has been shown to potentiate adrenergic venoconstriction
(Kadowitz, Sweet and Brody, 1972) and PGD2 and PGC2 potentiate
catecholamine induced venoconstriction, although to a lesser degree
than PGF^ (Jeffrey and Smith, 1977).
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A rise in peripheral resistance (Nakano and Cole, 1969) and central
effects (Sweet, Kadowitz and Brody, 1971; Lavery, Lowe and Scroop,
1971) have also been implicated in the pressor action of PGF^ .
According to Jones (1976) there are at least two'receptor types in
the vascular system responsible for prostaglandin effects, namely
the depressor effects due to E-like prostaglandins and pressor
responses due to D-like prostaglandins (i.e. PGA, PGC and PGF^"
respectively).
One problem in accepting an extrarenal role for renal prostaglandins
is the pulmonary degradation of PGE and PGF (Vane and Ferriera, 1967;
Robertson, 1975). PGA (Horton and Jones, 1969; Robertson, 1975),
PGC (Jones, 1972) and PGB (Robertson, 1975) all escape pulmonary
degradation. In the rat, unlike the dog, PGE is less efficiently
removed by the lungs (Papanicolou and Meyer, 1972).
Not all the pulmonary degradation products are without biological
action, however. In sheep, 15-oxo PGF^04 is 5 to 10 times more
active at raising BP than PGF^, whereas 15-oxo PGE^ is inactive
(Jones, 1975). 15-oxo PGA^ is inactive in rat, but the renal
metabolite of PGA^ 13,14 dihydro PGA^ is as active at reducing
BP as PGA2 (Lee, 1976) .
Prostaglandins in Experimental Flypertension
Rat kidney (Tobian et al, 1964) and cultured RICs. (Muirhead et al,
1973) are antihypertensive in the rat. The medulla from the
ischaemic kidney is more potent than normal medulla and that from
the untouched kidney is without activity (Manthorpe, 1973).
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There is evidence that renal prostaglandins do not mediate this
action in this species. Indomethacin treatment fails to prevent
the antihypertensive effect of implanted normal medulla (Manthorpe,
1975) and the lipids extracted from rat RICs incubated with
indomethacin are still antihypertensive (Muirhead, Leach, Germain,
Byers and Armstrong, 1974).
There are conflicting reports regarding renal levels of prostaglandins
in hypertensive rats. A rise in PGE is reported in the clipped kidney
(Somova, 1971; Jaffe, Parker, Marshall and Needleman, 1972).
In contrast a decreased synthetic capacity is reported in one and two
kidney Goldblatt rat and in the Japanese SHR, with a good correlation
with the degree of hypertension (Sirvio and Gagnon, 1974). Decreased
release is reported in the isolated kidney of Goldblatt rat CLeary,
Ledingham and Vane, 1974).
Prostaglandin synthetase inhibition produces hypertension in rats
but only after volume loading (Rosenthal et al, 1974) and renal
hypertension is exacerbated by indomethacin (Pugsley, Beilin and
Peto, 1976) and a variety of aspirin-like drugs (Scholkens and
Steinbach, 1975). However, meclofenamate has been reported to
produce a fall in BP during the acute phase of renal hypertension
in rats (McQueen and Bell, 1976).
PGE-j, E2, A-| and A2 are antihypertensive in the rat when injected
daily (i.p.) (Somova, 1972) although other workers claim higher
doses of PGE are required (Muirhead, Leach, Brown, Daniels and
Hinman, 1967; Wendling, Ducharme and Graham, 1972; McQueen and
Bell, 1976). A central action is also reported with PGA2 in the
SHR (Leach, Armstrong, Germain and Muirhead, 1973).
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The first report of hypertension after chronic treatment with
indomethacin was reported in the rabbit (Colina-Chourio, licGiff and
Nasjletti, 1975), however Muirhead, Brooks and Brosius (1976), failed
to repeat this.
In the dog the status of the renal prostaglandins in experimental
renal hypertension has been poorly documented despite the fact that
this species probably offers the best example of the antihypertensive
role of the kidney.
Acute reduction of RBF has been reported to release prostaglandins
(McGiff et al, 1970a; Herbazynska-Cedro and Vane, 1973) but this may
be a misinterpretation of the data (Beckman and Zehr, 1975) as
discussed in section 3.
During the acute phase of renal hypertension in the dog there is a
rise in output of prostaglandins from the untouched kidney (McGiff
et al, 1970a) probably due to the rise in angiotensin.
Oral' PGE^ given to one kidney Goldblatt dogs daily reduces BP
(Muirhead, Leach, Brooks, Brown, Daniels and Hinman, 1968b). In
the anaesthetised dog, prostaglandin synthetase inhibition raises
BP (Lonigro et al, 1973a).
The absence of reports of renal prostaglandin studies in conscious
renal hypertensive dogs prompted the present investigation.
SECTION I
RENAL VENOUS PROSTAGLANDINS IN
EXPERIMENTAL RENAL HYPERTENSION IN DOG
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Problems Encountered in Chronic Dog Work
In the course of this investigation,
with conscious catheterised dogs, we
which are discussed below.
having had no previous experience
encountered several problems,
Catheter Patency
The most noticeable early problem was that of catheter patency. In
the early preparations we used a skin button arrangement, containing
a valve as a means of exteriorizing the renal and jugular venous
catheter. The design was that of Day and Whiting (1972). In our
hands, the valves"occasionally leaked causing catheter blockage.
We eventually resorted to using metal luer fittings with metal
obturators.
Catheter block still proved a problem, but this was further reduced
by using PVC carotid and jugular catheters instead of nylon and the
use of silastic narrow bore tubing as the renal venous catheter.
Clotting within the carotid artery catheter was virtually eliminated
by ensuring that the catheter tip lay in the aortic arch and not
in the origin of the carotid artery, where the "dead" portion exists.
Having reduced the incidence of catheter blockage, the frequency of
catheters being pulled out rose and this was reduced by the use of a
subcutaneous collar around the catheter and by securing the catheters
externally in an elastic bandage placed around the neck of the dog.
Haemorrhage from the blood vessel, at the site of catheterisation
was prevented by double ligation distal to the point of entry.
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Infections
Systemic and local infections were particularly frequent in the
early experiments, manifesting themselves in the first 2-3 days after
the operation. On the advice of the Bacteriology Department, the
use of ampicillin as a post-operative prophylactic was abandoned
and thiomersal was included as an antiseptic in our surgical routine,
due to the high incidence of Pseudomonas pyocyanea infections.
Post-operative infections were consequently reduced in incidence
and only occasionally did sytemic infections arise, presumably due
to bacteria introduced during daily catheter flushing and during
fluid volume estimations. Benzylpenicillin with streptomycin
(Cristamycin, Glaxo] normally controlled such infections.
Post-operative Recovery
Poor abdominal wound healing tended to hinder the post-operative
recovery of some dogs and this was solved by changing from a median
to a para-median abdominal incision, which although technically more
difficult due to musculature and vasculature, resulted in a
mechanically stronger wound.
Animal Health and Size
General improvements in the preparations were also seen when more
rigorous attention was paid to the dogs' general health. Larger
dogs endured the operation better than the initial small ones and
eventually a source of reasonably healthy large foxhound bitches
was found. These were normally kept in the animal house for at
least 2 weeks prior to the operation and were fed on a standard diet
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with added ferrous sulphate.
The first completely successful dog, Sadie, was operated on November
1975. Thereafter all the foxhounds providing successful results,





On the morning of the operation, the dog was pre-medicated with
pethidine (Pethilorfan, Roche, 50 mg i.m.]. After 30 min, the dog
was taken to the preparation room, where the dorsal midline was
shaven, such that the dorsal midline could be marked as a guide to
catheter exteriorization during the operation. The dog was
anaesthetised with pentobarbitone (Nembutal, Abbott, 30 mg/kg, i.v.]
and the flanks, neck and abdomen clipped and the loose hair removed
with a vacuum cleaner. The shaved skin was swabbed with 3 antiseptics.
The first antiseptic used was Stericol (Sterling Industrial] ana this
was followed with alcoholic chlorhexidine (Hibitane, I.C.I.].
Immediately before incisions in the theatre, thiomersal solution
(0.1% w/v thiomersal in 50% ethanol, 25% acetone and 25% water]
was used.
Surgical procedures
The animal was carried into the operating theatre and secured on its
back to the operating table. A heating pad was placed under the
animal to maintain its temperature. A Venocath (Abbott] was inserted
into a saphenous vein for the infusion of Hartmann solution
(Steriflex No. 11, Allen and Hanburys Ltd] to maintain acid-base
balance and to replace fluid loss during the operation. Supplementary
doses of pentobarbitone were also administered by this route.
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Those participating in the sterile activities of the operation scrubbed
up and put on sterile masks, caps, gowns and gloves. The abdominal
site was draped, swabbed with thiomersal and the first incision, a
paramedian ventral incision was made with diathermy. This was
preferred to a ventral midline incision because of the greater strength
and healing ability. The muscle layers were split with blunt
dissection and diathermy. Bleeding was stopped by ligation or
coagulation. The peritoneum was opened and the gut exteriorized to
expose the right renal region. The peritoneum above the right renal
artery was cut and the artery freed for about 1 cm. The renal clamp
was introduced through a stab-wound at the subcostal angle and was
fitted around the renal artery. The silastic tube leading to the
clamp (1.6 mm i.d., 5.0 mm o.d.) was cut to size (60 - 100 mm in
length) and buried subcutaneously with a stopper and a loop of
thread to allow it to be retrieved at the time of clamping. The
stab-wound was stitched and the renal peritoneum repaired using
continuous stitches (3 metric, ivory thread, dersilk, Ethicon).
The peritoneum above the ovarian vein on the left side was incised
and the vein dissected free for about 2 - 3 cm to its junction with
the renal vein. The silastic renal venous catheter (Esco Ltd,
1.0 mm i.d., 2.0 mm o.d. and about 70 - 75 cm long, with side holes
/
in the last centimetre) was introduced into the abdomen through a
stab-wound from a track down the animal's back. Two collars were
placed around the catheter 3 cm from the tip to prevent the catheter
from being pushed or pulled from the required position. The catheter
was positioned such that the tip could be palpated in the renal vein.
The peritoneum was then repaired.
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In one dog (Sadie), the left renal artery was clamped such that the
sampling was from the clamped kidney (ipsilateral samples).
The ventral peritoneum was repaired using continuous stitches and
the muscle layers were drawn together with individual gut stitches
(4 metric. Chromic, Ethicon). Subcutaneous gut stitches were also
used and the skin was sutured with black silk (4 metric, Mersilk,
Ethicon).
On completion, the wound was irrigated with thiomersal and sprayed
with polymixin, neomycin and bacitracin (Polybactrin, BDH) and was
finally covered with a film of Nobecutane (BDH) and gauze.
The left common carotid artery and the right external jugular vein
were exposed after a midline ventral incision in the neck using
diathermy, followed by blunt dissection of the muscle. The arterial
and venous catheters (PVC, 30 - 35 cm long, 2.0 mm i.d., 3.0 mm o.d.,
with side holes in the venous catheter) were introduced at the back
of the neck, through the muscle and inserted into the vessels, such
that the tips were judged to be in the aortic-arch and in the
vena cava respectively. The arterial, central venous and renal
venous catheters were all led to the back of the neck and terminated
with metal luer fittings (BDB Products).
A mercury manometer was used to ensure that the arterial catheter had
not entered the left ventricle (mean pressure of about 70 mm Hg).
The neck was stitched and a tubular elastic bandage (Tubigrip, Seton
Products Ltd) was doubled and placed around the dog's neck. The
catheters were pulled through the inner layer and secured to the
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bandage. Their dead spaces (less than 1 ml) were cleared of the weak
heparin solution (100 p/ml) and refilled with 1000 jj/ml of heparinised
saline.
Post-operative care
On completion of surgery, the animal was removed to its kennel and
laid on an electric blanket to recover. The operation was normally
completed by 14.00 hours, taking less than 3 hours to perform.
By 17.00 hours the animal had usually recovered consciousness. Solid
food-was witheld for 24 hours, only water and milk with Complan
were allowed. Every morning, the dead spaces of the catheters were
removed and the catheters were flushed with sterile saline (10 ml
total each day) and the dead spaces refilled with 1000 u/ml heparinised
saline. On rare occasions the catheters blocked and streptokinase
(Kabikinase, Kabii) was injected or a sterile catheter wire was
pushed down.
Rectal temperature was taken daily and a progress chart kept. After
signs of infection, swabs^ were taken from any localising site for a
bacteriological report. Meanwhile 500 mg streptomycin and 300 mg
benzyl penicillin (Cristamycin, Glaxo) was given (i.m.) twice daily.
Fortunately all cases of infection responded to this regime.
The dogs were allowed one week to recover from the operation and they
were placed on a convalescent diet (Pedigree Pet Foods Ltd) with a
constant sodium content of 32 mEq/can. For a typical 20 kg dog on
two cans per day, this meant a solid food sodium intake of about




On the second week after the operation, the control parameters were
measured. The animals had been introduced to the laboratory
environment several times before the operation. At about 10.00 hours,
the dog was placed in a large basket and allowed to lie. The carotid
and central venous catheters were flushed and connected to
Consolidated Electrodynamic L223 transducers and the mean and
pulstatile pressures were recorded on magnetic tape (Bell and Howell,
7 channels, VR3200) for 3 minutes after the animal had settled.
In addition to BP and CVP, plasma volume (PV) and extracellular fluid
volume (ECFV) were also measured. All these control recordings were
made at least twice.
Arterial and renal venous blood samples were also taken for prosta¬
glandin (10 ml/sample] and renin (5 ml/sample] estimations.
i
Clamping operation
At the beginning of the third post-operative week, the animal was
made hypertensive by partially clamping the renal artery. Under
thiopentone (Pentothal, Abbott) anaesthesia, the clamp tubing was
located under a cut-down and the long blade screwdriver inserted
down the tube to locate the screw. The screw was turned to occlude
the artery completely and then screwed back 1| turns (0.8 mm). This
normally produced a rise in BP within a few seconds.
Figure 1 Renal artery clamp showing locking screw on the right
with the vertically moving occluding screw within the
'U'-shaped tail-piece. The scale on the right is in
millimetres.
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The clamp used in this study was a modification of that designed
by Ferrario, Blumle, Nadzam and McCubbin (1971). Essentially it
consisted of a head-piece with a small screw, which could be screwed
down to compress the artery, which lay in the 'U'-shaped tail-piece.
The clamp was modified by a locking screw, since in early studies it
was found that the clamp could spring apart if the compressing
screw was lowered. The clamp was made from high quality surgical
steel by Mr G Campbell of the departmental workshop (see Figure 1).
In some of the early dogs, intravenous pyelograms (ivp) were performed
to gain some indication as to the extent of clamping as judged by
preservation of renal function. Figure 2 shows the ivp of Melody
3 days after clamping. Bilateral function was present,
Hypertension period
During the next 2 to 3 weeks, the hypertension was monitored by
measuring BP, CVP, PV, ECFV, haematocrit (Ht), plasma sodium and
potassium, renin and prostaglandins at regular intervals.
Blood collection
10 ml blood samples from the arterial and renal venous catheters
were used for prostaglandin estimations. "' These samples were
immediately placed in 10 ml conical centrifuge tubes, containing
heparin and surrounded with ice.
5 ml blood samples were used for renin estimation and these were




X-ray of Melody, 2 days
after clamping the right
renal artery. The outline
of the clamp and its
locking screw are clearly
visible.
Figure 2b
2 minutes after injection
of the radio-opaque material
into the left renal venous
catheter. The material is
present in the full length
of the right ureter and is
beginning to fill the left
ureter.
Figure 2c
6 minutes after injection,
the full length of the left
ureter is visible and the
right renal calyces are
now visible. The bladder
can be faintly seen.
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The blood was centrifuged as soon as possible at 4°C, 15,000 g for
25 min and the plasma decanted and placed in labelled blood tubes,
which were stored in a freezer until assay.
Haemodynamic measurements
The BP and CVP signals were played back on the tape recorder and
displayed permanently on light sensitive paper (Honeywell, Visicorder,
2206).
Heart rate (HR) was computed by a programme patched on an analogue
computer (EAL 380) . The positive first differential of the BP pulse
was used to trigger a time ramp, which was reset and immediately set
in the integrate mode by the next rise in BP. The peak voltage' of
the time ramp was stored by 2 track/store amplifiers in series and
this value (heart period), was fed into a divider unit to obtain
heart rate on a beat by beat basis. The system was calibrated by
use of the mode timer set to 500 + 500 msec (60 beats/min) and 200
+ 300 msec (120 beats/min). HR was also recorded on the light
sensitive paper.
Fluid volume estimations
PV and ECFV were measured by estimating the dilution of injected
material.
A control sample of arterial blood (5 ml) was taken and the haematocrit
estimated using microhaematocrit tubes. After centrifuging, 0.5 ml
plasma was used for estimation of control levels for the PV estimation
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and a further 0.5 ml for the ECFV control estimation. 1.0 ml was
used for plasma electrolyte estimation.
After injection of the tissue fluid markers, 2 x 1.5 ml blood samples
were removed after 10 and 90 min for PV and ECFV estimation
respectively CO.5 ml plasma in each case).
A total of 8 ml blood was used for each series of fluid volume measure¬
ments. The exact methods for these measurements are as follows:-
Plasma volume (PV) estimation
T-1B24 (Evans Blue) is an azo dye, which binds to plasma proteins and
leaves the vascular compartment at a very slow rate (Gibson and Evans,
1937). It is possible to estimate plasma volume (PV) from the dilution
of a known amount of injected T-1824. Since the rate of disappearance
is slow and equilibrium occurs within three minutes (Surtsin and Rolf,
1950) a blood sample taken 10 minutes after injection can be used to
estimate PV (Bianchi, Tenconi and Lucca, 1970j Ferrario, 1974).
Haemolysis and lipaemia interfere with the spectrophotometric deter¬
mination of T-1824 and several workers employ extraction techniques
or use several wavelengths to correct for interference. In the
present experiments T-1824 was still detectable from previous tests
and as a result plasma samples were taken before each test to correct
for circulating T-1824. This also corrected for any lipaemia.
Haemolysis was found to cause negligible interference despite large
absorption peaks at 415, 545 and 580 nm, characteristic of haemoglobin.
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The T-1824 was made up in batches by dissolving the powder (Gurr)
in sterile 0.9% saline (Steriflex No. 1, Allen and Hanburys Ltd)
to give a final concentration of 4 mg ml-'' . The solution was
filtered through a Millipore filter (microsyringe filter with a
0.22 p filter) into ampoules, which were sealed for future use.
6 ml (24 mg) was injected into the jugular vein catheter and washed
in with saline after a control arterial sample had been taken. After
10 minutes, an arterial sample (1.5 ml) was withdrawn and the plasma
removed after centrifugation for T-1824 estimation. Haematocrit was
measured using microhaematocrit tubes (USE).
In view of the fact that T-1824 slowly degrades in light and to avoid
errors in making fresh standards each time, the injectate solution
was used to make three standard solutions. 0.5 ml of injectate was
dissolved in saline (50 ml) for the preparation of solutions equal
to 200, 400 and 800 times the dilution of the injectate as shown
in Table 1.
T-1824 in plasma has an absorption peak at 625 nm but in saline the
0D at 625 is lower for a given concentration and the peak absorption
is at 605 nm and is pH dependent. In phosphate buffer (pH 7.4) peak
absorption is also at 605 nm but the reading at 625 nm is equivalent
to that in plasma. Therefore the standards, dissolved in phosphate

























The reciprocal of the dilution factors 200, 400 and 800 times,
5 x 10"^, 2.5 x 10~3 ancj 1,25 x 10"^ plotted against the 0D at
625 nm is linear and the plasma dilution factor can be read from
this graph and PV estimated from:-
PV = injectate volume (ml] x dilution factor
4
and blood volume (BV) = PV
1-Ht
Extracellular fluid volume (ECFV) estimation
ECFV was estimated by measuring the extent of dilution of potassium
thiocyanate (KSCN) as first described by Ashworth, Nuirhead, Thomas
and Hill [1943).
The thiocyanate anion distributes itself fairly evenly over the first
4 hours and is excreted at about 2.3% per hour. To avoid blood loss,
rather than take several samples and extrapolate to zero time, a 90
minute sample was taken (Bianchi, Tenconi and Lucca, 1970). This
method tends to overestimate ECFV because KSCN enters the cells of
the gastric mucosa and erythrocytes CAshworth et al, 1943) but it
can nevertheless be used as an index of ECFV changes (Levitt and
Gaudino, 1950) .
Thiocyanate (BDH, Analar) was made in batches by dissolving the
powder in 0.9% saline to give a final concentration of 50 mg ml
The solution was passed through a Millipore filter and ampouled.
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A control arterial blood sample was used to correct for endogenous
levels and circulating thiocyanate from previous tests. 10 ml of
_ A
thiocyanate (about 25 mg kg ) solution was injected into the jugular
vein catheter over one minute. Rapid injection resulted in cardiac
arrest in one dog because the thiocyanate ion is a powerful stimulant
of cardiac tissue. After 90 minutes an arterial blood sample (1.5 mil
was taken and centrifuged and the plasma analysed for thiocyanate
after the method of Elkington and Taffel (1942).
Plasma protein of both the control and 90 minute samples was precipi¬
tated using 2 ml of 10% trichloro-acetic acid, whilst vortexing on
a 'Whirlimix'. After centrifugation, the supernatant was removed and
reacted with 2.5% (w/v) ferric nitrate in 10% nitric acid, resulting
in an orange coloured solution. These were compared with standard
solutions by reading the absorption at 460 nm in a spectrophotometer
(Eausch and Lomb, SP 20).
The standard stock solution of 15 pig ml was used to give standards
of 2.5, 5 and 10 pig ml""'. The injectate was diluted 1:2500 (0.1 ml
in 250 ml) and assayed in triplicate to obtain an accurate estimation
of the concentration injected. The control and 90 minute samples
were measured in duplicate. See Table 2.
Immediately after adding the ferric nitrate reagent, the tubes were
mixed and read at 460 nm. ECFV was calculated from:-
ECFV = injected volume (ml) x injectate cone, (mg ml""^)






































Interstitial fluid volume (IFV) was calculated from the difference
of ECFV and PV and the ratio PV/IFV was used as an index of fluid
distribution between the vascular and the extravascular compartments.
An abnormal distribution is reported in Goldblatt rat (Lucas and
Floyer, 1974) and in hypertensive man (Tarazi, Dustan and Frohlich,
1969).
Plasma sodium and potassium concentrations
1.0 ml of plasma was diluted to 50 ml by dissolving in 49 ml of distilled
+ +
water for K estimation and 2 ml of this was diluted to 10 ml for Na
estimation using a flame photometer (EEL).
The sodium standards were prepared from a stock solution of sodium
chloride (100 mEq litre"'') by making 0.4, 0.5 and 0.6 ml of this
solution up to 100 ml. This produced solutions of 0.4, 0.5 and 0.6
— 1 +
mEq litre equivalent to plasma Na concentrations of 100, 125 and
150 mEq litre respectively.
Since potassium interferes with the sodium estimation (the reverse
is not true), 0.2 ml of 10 mEq litre K.C1 was added to each standard.
_ A +
This is equivalent to a plasma concentration of 5 mEq litre K .
+ A
The K standards were prepared from a stock solution of 10 mEq litre
KC1 by dilution of 0.6, 0.9 and 1.2 ml of 100 ml to give solutions
of 0.06, 0.09 and 0.12 mEq l"-*, equivalent to plasma concentrations
__
of 3.0, 4.5 and 6.0 mEq litre respectively.
These standards gave a linear calibration, from which the plasma
concentrations could be calculated.
Prostaglandin Radioimmunoassay (RIA)
Prostaglandin and F©< and B^ antibodies were raised in rabbits and
PGA^ antibody was raised in sheep. The most suitable antisera were




PGE^ was conjugated to bovine thyroglobulin (Tg] using the carbodiimide
reaction. After 4 hr of incubation at room temperature, the mixture
was dialysed in phosphate buffer for 10 hr, against running water.
After dialysis, the retentate was centrifuged for 20 min at 40°C and
15,000 g and the supernatant was freeze-dried to yield PGE^-Tg
conjugate. Each mole of thyroglobulin bound 334 moles of PGE^.
PGA,., and PGB^ were also conjugated to Tg.
PGF2<x was conjugated to bovine serum albumin (BSA] by the mixed
anhydride reaction. After incubation at about 0°C for 4 hr, the
solution was dialysed for 48 hr against running water. The conjugate
obtained had about 20 - 37 moles of PGF^0'- bound to each mole of BSA.
B. Injection regimen
White New Zealand rabbits were injected intradermally, on the shaved
back, at about 50 sites with a total of 100 jjg conjugate in 2 ml of
Freund's complete adjuvant. Booster injections were given every 6
weeks at 4 sites (suprascapular and femoral] using about 250 jjg/site.
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Three sheep were used to raise the PGA antibodies and these were
injected subcuta.neously on the back at regular intervals.
C. Blood collection
The rabbits were bled at regular intervals after the first boost,
from the marginal ear vein, to provide about 50 ml of blood each
time. The blood was allowed to clot at room temperature and then
left overnight at 4°C. The serum was centrifuged at 1,000 g for
2 min at 4°C and then decomplemented at 56°C for 30 min. Sodium
azide (0.1 ml of a 10 mg/ml solution to every 10 ml of serum) was
added and the serum was stored in sterile McCartney bottles, in
aliquots of 2 ml, at -20°C. The sheep were regularly bled from an
external jugular vein and the blood treated in the same way.
Extraction Procedure
500 pi of plasma was routinely assayed, but in some cases when levels
were low, the assay was repeated using 1 ml. The plasma was acidified
to a pH of 5.0 with 1.0 MHC1 (approximately 20-40 pi). The addition
of petroleum ether at this stage to remove the neutral lipids does
not improve the assay and so was omitted in the extraction procedure.
The prostaglandins were extracted twice in 6 volumes of ethyl acetate
and the combined ethyl acetate fractions were washed with 500 ul of
distilled water and evaporated to dryness. The dry extract was
dissolved in 400 pi of 60:40:20 toluene/ethyl acetate/methanol and
diluted with 600 pi of 60:40:0 and left overnight at -20°C. The
3
extraction recoveries of added H-prostaglandins were 56 +_ 13 for
PGA2, 78 +_ 11 for PGE2, 86 _+ 9 for PFG^ and 85 _+ 12 for PGB2 (mean
+ s.d., n = 12).
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Chromatographic Separation
Small columns [Pasteur micropipettes, 100 x 5 mm] were filled with
0.5 gm slurry of silicic acid (Sigma, 100-300 mesh) in 60:40:0.
Each column was pre-washed with 5 ml of 60:40:20 and 2 ml of
60:40:0 and the extracted prostaglandins were added to the columns
and flushed twice with 250 jj 1 of 60:40:0.
The following fractions were obtained
Fraction 1 - eluted with 6 ml 60:40:0.5, consisting of
the A and B prostaglandins.
Fraction 2 - eluted with 12 ml 60:40:1, consisting of E
metabolites.
Fraction 3 - eluted with 6 ml of 60:40:3, consisting of PGE.
Fraction 4 - eluted with 4 ml 60:40:20, consisting of PGF.
Fractions 1, 3 and 4 were evaporated to dryness, ready for radio¬
immunoassay.
Column recoveries were between 40 and 65%.
Radioimmunoassay Procedures
A. Dilution Curves
The antisera was diluted in a series of 2-fold dilutions using
diluent (0.05 M tris buffer with a pH of 6.8 for the PGE antibody
and 7.3 for the PGF antibody]. To each tube containing 1 ml of
antiserum, 50 pi of tracer solution (20 pg PGE^ and PGF^f*, 120,000 -
170,000 mCi/mmol, Hamersham] was added and the tubes were incubated
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for 2 hr at 4°C. After incubation, 50 pi of diluted normal rabbit
antiserum was added and the solution left to equilibrate for 10 min.
50 jjI of donkey rabbit antiserum (DARS, Wellcome Reagents, 3 in 10
dilution) was added and after 16 hr of incubation at 4°C, the tubes
were centrifuged at 4°C for 45 min at 1500 g. 0.6 ml of supernatant
was transferred to a vial of scintillant (PPO and DklPOPPOP, 13 ml)
and counted for 4 or 10 min on a Nuclear Chicago liquid scintillation
counter, with a counting efficiency of about 30%. The PGB antibody
was treated similarly to the PGE and PGF antibodies. PGA antibody
was also similarly treated, with the substitution of donkey
anti-sheep serum (DASS) for the DARS.
A final dilution curve was chosen, which gave a binding of about
60% of the tracer in the absence of "cold" standard.
B. Standard Curves
Duplicate standard tubes were used in the range 10 pg to 5.1 ng of
unlabelled prostaglandin standard made up to a final volume of
0.75 ml in diluent. Tracer C50 pi) solution was added and allowed
to equilibrate for 10 min. Diluted antiserum C50 pi) was added and
the tubes were incubated at 4°C for 2 hr. Diluted normal rabbit
serum (50 pi) was added to the PGF assay tubes only and left to
equilibrate for 10 min. Diluted DARS (50 pi) was added and the tubes
incubated for 16 hr at 4°C. After the incubation, the tubes were
centrifuged at 4°C, 1200 g for 45 min and 0.75 ml of the supernatant
was mixed with 13 ml of scintillant and counted.
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Quadruplicate zero standards, solvent blanks, non-specific blanks
and counting standard tubes were used, containing 0.75 ml diluent.
50 ul of tracer was added to each tube and after 10 min equilibration,
diluted anti-serum was added to each tube, with the exception of the
blanks and counting standards. All the tubes were then treated like
the unknown tubes, with the exception of the counting standards.
C. Cross Reaction of the Antibodies
Cross reaction of the antisera was calculated from the amount of
prostaglandin required to produce a 50% fall in binding obtained
with the zero standard. For example the percentage cross reaction
of PGA2 with the PGE^ antiserum is:-
Amount of PGE„ producing 50% of zero standard binding
£ x 100
Amount of PGA^ producing 50% of zero standard binding
For the PGE^ antibody, the antiserum from rabbit 7 (3rd bleed,
21 weeks after the first boost} was used at a final dilution of
1/2,000 and gave the following cross reactions:-
PGE1 100%
PGA and B groups 2%
13,14-dihydro-15-keto PGE2 5%
Sensitivity, defined as the amount of prostglandin required to produce
a 10% fall in zero standard binding, was 30 pg/tube.
The PGF2« antiserum was from rabbit 4 C5th bleed, 35 weeks after the
first boost} and was used at a final dilution of 1/55,000 and gave
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other pg groups <1%
The level of detection was 45 pg/tube.
The use of silicic acid column chromatography further reduced the
interference of the other prostaglandins. Since the PGE2 and
PGF^ antibodies can not distinguish between PGE2 and PGE^
and PGF2<* and PGF^ot respectively, the reported concentrations are
expressed as pge and pgf.
The PGA2 antiserum from sheep number- 2 C7th bleed) was used at a





PGE1 and 2 3%
PGF2cx
The PGB2 antiserum from rabbit number 7 (first bleed) was used at a













Figures 3 and 4 show the standard curves obtained in 12 consecutive
assays [mean +_ s.d.) over a 6 month period.
The intra-assay precision varied between 10 and 15%.
A more detailed account of the method of raising the PGF^ antibodies
and of the radioimmunoassay method employed has been published
(Dighe, Emslie, Henderson, Rutherford and Simon, 1975],
The PGA and PGB analyses were performed late in the completion of
the thesis. In addition the majority of samples could not be
assayed due to loss of the antibodies in a laboratory fire.
Consequently the results of four animals will be briefly presented.
PG activities are presented as plasma concentrations, and are









































































Plasma renin activity (PRA) was measured by means of an angiotensin
I radioimmunoassay kit (CEA:IRE:S0RIN, Italy), which measures the
amount of angiotensin I generated during plasma incubation.
A. Blood Collection
Arterial and renal venous blood samples (10 ml) were collected in
ice-cold centrifuge tubes containing 4 mg of disodium EDTA to inhibit
clotting and angiotensinase. Samples were collected before, and 2, 5
and in some cases 14 and 21 days after, clamping. Each sample was
centrifuged at 15,000 g for 25 min at 4°C and the plasma stored
at -10°C until assay.
B. Renin Activity Estimation
Angiotensinase inhibitors (2-3,dimercaptopropanol and 8-hydroxy
quinoline, 0.4 ml) were added to 0.4 ml of each plasma sample and
then divided into 2 portions, one of which was incubated at 37°C and
the other at 2-4°C for 1.5 hour. The latter allowed measurement of
endogenous angiotensin I such that a correction could be made in
estimating PRA. An optimum pH of 5.6 - 5.8 was used during the
incubation.
Standard tubes of 0.5 - 8.0 ng/ml ileu-5-angiotensin I were made up
in phosphate buffer using 100 pi of solution. 100 pi of ^5I-
angiotensin I was added to each tube after 100 pi of rabbit angiotensin
I antiserum, with the exception of the "total counts" tube, which
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received no antiserum. The amount of antiserum used was calculated
to give a binding of between 30-60% of the labelled angiotensin in
the absence of unlabelled angiotensin. Incubated plasma samples
(100 pi) were added to the unknown tubes. After vortexing, the
tubes were incubated for 4-24 hours at 2-4°C. At the end of this
period, the standard tubes were given 100 pi of "lyophilized
serum" and the other tubes received 100 pi of buffer.
Dextran coated charcoal (0.5 ml) was added to each tube whilst
vortexing and after 10 min the tubes were centrifuged at 1,500-
2,000 g for 10 min. The supernatants (0.8 ml) were counted and
from the standard curve, the amount of angiotensin I was calculated.
PRA is expressed as the amount of angiotensin I generated over a
1 hr period by 1 ml of plasma after correction for the basal
angiotensin I.
It is realised that this method may not give an accurate estimation
of PRA because it is assumed that the reaction kinetics are zero
order even after 1.5 hours. Since no exogenous substrate was added,
this may not have been true in every case.
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RESULTS
Of the 12 dogs successfully taken to the clamping stage, 7 (Melody,
Jolly, Flora, Apricot, Sadie, Mandoline and Whisper) became
hypertensive in the days following, 1 became transiently hypertensive
(Trinket) and 4 (Acorn, Jigsaw, Joyless and Topaz) failed to become
hypertensive.
Post mortem examination revealed that in Joyless, the clamp had not
been screwed down and consequently this animal can be considered
to be sham-operated. Topaz failed to become hypertensive because
the clamp was on a branch of a bifurcating renal artery. No obvious
reasons for failure were evident in Jigsaw or Acorn.
Hypertensive Dogs
Grouped data is shown in Figure 5 and Table 3. Individual data is
shown in Figures 6-13 and Tables A-L.
A. Blood Pressure (BP)
For the purpose of grouping the hypertensive dogs. Flora was omitted
because of the anomalous behaviour of her body fluids. In the
remaining 6 dogs, BP rose from 122 4.4 mmHg (n=6), to 136 +_ 6.3 mmHg
(n=4) on the first day and reached a peak of 148 +_ 5.2 mmHg (n=6),
P<0.005, by the second day. Hypertension remained stable over the
remaining days at about 142 mmHg. Thus as a group, the hypertension

















































Figure 5: Grouped data from 6 hypertensive dogs. The
prostaglandin data is from 3 of these dogs.
* P<0.05; + PCQ.01
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Table 3: Hypertensive Dogs
GROUPED DATA N is the number of paired observations
BP (mmHg) N P HR (bpm) N P
C 123 + 5 6 C 85 + 3 6
1 137 + 7 4 ns 1 95 + 11 4 ns
2-3 148 + 6 6 <0.005 2-3 79 + 5 6 ns
4-5 142 + 4 6 40.025 4-5 75 + 7 6 ns
7 142 + 6 5 <0.05 7 82 8 5 ns
9-11 145 + 6 6 <0.01 9-11 78 + 8 . 6 ns
CVP (mmHg) PV (ml/kg)
C 3.3 + 0.5 6 C 64.9 + 1.8 6
1 4.4 + 1.2 3 <0. 05 2 71 .1 + 3.2 5 ns
2-3 5.7 + 1.4 5 ns 4 72.0 + 2.9 6 <0.05
4-5 6.3 + 1.7 6 <0. 05 7 69.1 + 2.9 4 ns
7 5.9 + 1.1 4 <0.05 11 66.5 + 3.8 5 ns
9-11 5.4 + 0.5 4 ns
ECFV (ml/kg) PV/IFV
C 327 + 8 6 C 0.25 + 0.01 6
2 362 + 19 5 ns 2 0.25 + 0.02 5 ns
4 349 + 10 6 ns 4 0.26 + 0.02 6 ns
7 338 + 28 4 ns 7 0.26 + 0.01 4 ns
11 335 + 19 5 ns 11 0.24 + 0.02 5 ns
l\la+ (mEq/1) K+ (mEq/1)
C 150 + 3 6 C 3.9 + 0.2 6
2 152 + 4 5 ns 2 3.7 + 0.2 5 ns
4 147 + 1 6 ns 4 3.8 + 0.2 6 ns
7 138 + 8 4 ns 7 3.7 + 0.2 4 ns
11 153 + 7 5 ns 11 4.0 + 0.2 5 ns
PGE (pg/ml) PGF (pg/ml)
C 1 55 + 27 3 C 209 + 22 3
2 364 + 75 3 <0.05 2 315 + 65 3 ns
5 670 + 196 3 <0.05 5 477 + 20 3 <0.005
7 378 + 89 3 <0.05 7 278 + 125 3 ns
10 290 + 160 ■ 3 ns 10 223 + 103 2 ns
C - control data before clamping. Figures are days after clamping.
Values mean + S.E.
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The same trend was seen in the individual dogs, although the absolute
rises varied from 6 mmHg in Whisper, 9 mmHg in Mandoline, 12 mmHg in
Sadie, 20 mmHg in Apricot, 34 mmHg in Melody and 38 mmHg in Jolly.
All the dogs had a resting BP of between 110 and 120 mmHg, with the
exception of Mandoline C145 mmHg). Flora, not included in the grouped
data, had the severest hypertension of about 50 mmHg 4 days after
clamping.
B. Heart Rate (HR)
Grouped HR showed no change, 85 + 2.5 beats/min (n=6) before and
95 +_ 7.2 beats/min Cn=4) one day after clamping. Only 14 days after
clamping did HR fall significantly below control to 74 +_ 3.8 beats/min
(n=3, P<0.05), but this may be due to the low sample number
C. Central Venous Pressure (CVP)
CVP rose from 3.3 +_ 0.4 mmHg t.n=6) to 5.9 _+ 1.0 mmHg (n=4, P<0.05)
7 days after clamping but by day 16 had returned to control
(4.0 +_ 1.3 mmHg, n=3) .
D. Fluid Volumes
All the hypertensive dogs, with the exception of Flora, showed a
transient retention of fluid.
Plasma volume (PV) rose from 64,9 +_ 1.6 ml/kg (n=6) to 72.0 _+ 2.7 ml/kg
(n=6, P<0.05) 4 days after clamping and returned to control over the
subsequent days.
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Extracellular fluid volume (ECFV) showed a similar pattern although
the peak increase was noted earlier, 2 days after clamping, having
risen from 327 _+ 7.5 ml/kg (n=6) to 362 _+ 17.2 ml/kg [n=5) and
348 _+ 9.1 ml/kg (n = 6) 2 and 4 days after clamping respectively.
In both cases the rises just failed to reach the 5% significance
level (P<0.1 in both cases).
No change in the distribution of extracellular fluid as judged by
PV/IFV could be detected, with a control of 0.24 _+_ 0.11 (n=6) and
0.26 +_ 0.01 (n=6), 4 days after clamping.
D. Plasma Electrolytes
Plasma sodium and potassium concentrations did not change signifi¬
cantly from control values of 150 _+ 2.6 mEq/litre (n = 6) and
3.89 _+ 0.18 mEq/litre (n=6) respectively.
E. Renal Venous Prostaglandins
In 3 dogs, which became hypertensive and in which the renal venous
catheters were still functional (Jolly, Melody and Mandoline), a
transient rise in renal venous PGE and PGF concentrations occurred.
PGE concentrations rose from a control of 155 _+ 27 pg/ml (n=3) to
364 +_ 75, 670 +_ 196 and then fell to 378 +_ 89 pg/ml (all n=3 and
P<0.05), 2, 5 and 7 days respectively after clamping. By the tenth
day PGE levels had returned to control, 291 160 pg/ml (n=3).
PGF rose also from 209 _+ 22 pg/ml to 315 _+_ 65, 477 +_ 20 pg/ml and
then fell to 278 +_ 125 pg/ml ln=3 ] 2, 5 and 6 days after clamping
and had returned to 223 +_ 103 pg/ml Cn=2D 10 days after clamping.
Only the rise on day 5 reached significant levels (P<0.005}.
In each of these 3 dogs, control PGF concentrations exceeded the
PGE concentrations, but with the onset of hypertension the PGE
concentrations exceeded the PGF concentrations, with the exception
of Jolly.
Both Jolly and Melody showed a sharp rise in both prostaglandins,
reaching a peak 5 days after clamping. PGE rose to 2.3 and 7.5
fold of control from controls of 130 and 129 pg/ml and PGF rose to
2.6 and 2.5 fold of control from 200 and 175 pg/ml respectively.
See Figures 6 and 7.
PGE rose biphasically in Mandoline, peaking at days 5 and 10, but
this may be due to a false low estimate on day 7 or a false high
estimate on day 10. The peak PGE on day 5 was 735 pg/ml, 3.5 fold
that of control (210 pg/ml] and PGF rose to a peak of 525 pg/ml,
2.1 fold that of control (250 pg/ml]. See Figure 8.
In Sadie, in which the clamped kidney's renal venous blood was
sampled, PGE and PGF levels rose, but peaked earlier, at 1 and 2
days after clamping, rising to 535 pg/ml and 280 pg/ml, 2.35 and
2.61 fold of control for PGE and PGF respectively. By the 5th day
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Figure 9: "Sadie" In this dog the renal venous blood
from the kidney opposite the clamped
kidney, was sampled.
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PGA and PGB levels were measured in Jolly and Sadie. Unlike the
renal venous PGE and F concentrations, PGA levels in fact fell with
the progression of hypertension in Jolly, from 600 to 330 pg/ml
and below sensitivity, whereas PGB rose from 420 pg/ml reaching a
peak of 1035 pg/ml at day 7 (Table A).
The renal venous plasma from the ipsilateral kidney of Sadie showed
a biphasic rise in PGA and PGB, rising from 1415 and 2730 pg/ml
respectively to 2820 and 2790 pg/ml, 3 and 7 days post clamp for
PGA and 4420 and 4510 pg/ml on days 3 and 12 for PGB, unlike PGE
and F, which peaked on day 1 only (Table 03 .
Arterial PGE and F levels of these dogs failed to show a trend,
unlike the PGA and B levels, which closely followed the renal venous
levels in time course and levels.
F. Renin Activities
A rise in the arterial renin activities was seen in Melody and Mandoline
rising from 2.1 to 2.8 and 3.6 to 8.0 ng ml"'' hr"'' of angiotensin I
respectively 2 days after clamping. The levels quickly returned to
normal and by the 5th day were indistinguishable from control (1.1
and 2.0 ng ml"'' hr"'' angiotensin I respectively). With the onset
of hypertension renin release was suppressed in the untouched
kidney as judged by the VA differences (Table 4),
Flora (Figure 10) showed the severest hypertension, with a rise in
BP from a mean control of 128 mmHg to 170 mmHg 5 days after clamping.
Thereafter BP varied between 133 and 152 mmHg between days 7 to 17.
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Figure 10: "Flora" Blood from the inferior vena cava
was sampled for prostaglandin
activity
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Table 4: Arterial Renin Activity CARA)
Dog Day ARA VA difference
Melody C 2.1 -0.3
2 2.8 -0.3
5 1 .1 + 1 .4




21 4.8 -1 .2
Apricot C 2.8 -
2 12.4 -
5 10.0 -
Acorn C 1.2 +0.4
2 6.0 0
5 2.8 -0.8
14 1.2 + 0.8
Dogs Melody, Mandoline and Apricot became hypertensive, however
no renal venous blood was sampled in Apricot. Acorn did not become
hypertensive but she lost 50% of her blood volume on day 1 .
ARA is expressed in ng ml"'' hr-'' of generated angiotensin I.
The VA difference is the renal venous concentration [contralateral
Kidney!) minus the arterial concentration and is an index of renin
secretion.
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Both PV and ECFV fell with the onset of hypertension, unlike the
other hypertensive dogs. After days 5-7 fluid retention occurred.
PGE and F renal venous concentrations did not deviate from control
levels of 110 and 190 pg/ml respectively. However, at post mortem,
the catheter tip was found to be lying in the inferiour vena cava
as suggested by the ivp taken 3 days after clamping.
PGA and B concentrations rose transiently in the "renal venous"
and arterial plasma of this dog reaching a peak on the 5th day.
PGA showed almost a 10-fold rise in "renal venous" levels from
1500 pg/ml to 10,400 pg/ml, whereas the rise in PGB was smaller,
565 pg/ml to 2,705 pg/ml. Arterial levels of both these
prostaglandins showed a similar time course of changes (Table E].
Similarly in Apricot (Figure 11] the renal venous catheter was
found to be sampling vena caval' blood. Despite hypertension,
inferior vena caval plasma PGE and PGF concentrations did not
change from control (128 pg/ml and 140 pg/ml respectively]. PGA
and PGB arterial and vena caval concentrations transiently rose,
peaking on day 2. The vena caval PGA levels rose from 680 pg/ml
to 1,050 pg/ml and PGB rose from 145 pg/ml to 710 pg/ml (Table F].
Arterial renin activity rose transiently, peaking at day 2, having
risen from a control of 2.8 ng.ml~^hr_/' angiotensin I to 12.4
ng .ml-'' hr~1 angiotensin I (Table 4],
Due to a fault in the storage freezer the plasma from the hyper¬













































Figure 11 : "Apricot" Blood was sampled from the inferior
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Figure i2: "Acorn" This dog failed to become hypertensive
but on the day following clamping lost
50% of her blood volume.
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freeze properly resulting in a loss of prostaglandin activity.
The ria and extraction procedure were absolved from blame since
4 samples from Trinket, repeated because of poor replication,
gave reasonable results.
Non-hypertensive Dogs
In one dog, Acorn, (Figure 12] the arterial catheter obturator
accidentally came loose, the day after clamping, resulting in a
50% loss of blood volume.
Red cell volume, calculated from PV and Ht, fell from 55.4 ml/kg
to 28.9 ml/kg. PV rose from 72.1 to 78.4, 77.5 and 85.7 ml/kg,
1, 2 and 10 days later, whilst ECFV rose transiently from 300 to
3B7 and 401 ml/kg, 1 and 2 days after and then fell to control,
314 and 308 ml/kg, 10 and 17 days after the "haemorrhage" as BV
and Ht returned to normal.
Renal Venous Prostaglandin Concentrations
Renal venous prostaglandins showed no change with the exception
of a large transient increase in PGE only from 180 pg/ml to
400 pg/ml 1 day after the "haemorrhage", well outside the
intra-assay covariance limits (10-15%). Arterial prostaglandin
concentrations showed no trend.
Renin Activities
The day after the "haemorrhage" (day 2) as the renal venous PGE
reached a transient peak, arterial PRA also showed a sharp rise
\ 'v
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from 1.2 ng ml hr~1 angiotensin I to 6.0 ng ml~1hr~/' angiotensin I,
falling to 2.8 and 1,2 ng ml~/'hr~'' angiotensin I on days 5 and 14
respectively (Table 4).
A transient rise in BP was seen in Trinket (Figure 13), with BP
rising from 110 to 126 mmHg, 2 days after clamping, whilst PV and
ECFV transiently rose from 63.4 to 69.2, and 337 to 365 ml/kg, 2
days after clamping respectively. CVP rose from 4.4 to 6.7 mmHg
and HR fell from 89 to 56 beats/min and thereafter all parameters
returned to normal. Renal venous PGE and PGF concentrations rose
from a mean of 185 and 106 pg/ml to 352 and 360 pg/ml respectively
2 days post clamp and did not return to control even by the 10th
day (258 and 296 pg/ml respectively).
No hypertension was seen in Jigsaw and as the carotid catheter had
entered the left ventricle, the experiment was terminated (Table L).
Topaz also failed to become hypertensive (BP of 106 mmHg) and PV
and ECFV rose from mean controls of 71.6 and 336 ml/kg to 75.2 and
357 ml/kg 4 days after clamping. HR did not change and CVP fell
to 50% of control from 4.3 mmHg before rising again to control.
Due to the freezer fault no prostaglandin levels were detectable
(Table J).
Generally there was about a 2:1 ratio of renal venous PGE to PGF
as shown in Figure 14, taken from 7 dogs, which agrees with the
figures reported for the kidney COavis and Horton, 1972; Lonigro







































Figure 13: "Trinket" Only transient hypertension was
seen in this dog.
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Figure 14: Correlation of renal venous PGE2 and PGF^ in 7





Indomethacin (Indocid, Merck, Sharpe and Dohme, 50 mg orally, bid)
failed to alter the BP of a non-hypertensive dog, Joyless, when
given on day 7 after clamping, for 3 days, despite a fall in central
venous PGE and PGF from 515 to 210 pg/ml and 216 to 160 pg/ml
respectively. Similar pretreatment in a hypertensive dog,
Whisper, for 4 and 5 days also failed to alter BP (see Tables K
and I respectively) .
PGE2 Infusion
PGE^ was infused into Jigsaw and Whisper to study the effects of
acute infusions at rates comparable to peak renal release. The.
largest change in renal release of PGE was seen in Melody, with
a peak of 973 pg/ml, 5 days after clamping. Assuming a Ht of
50 and RBF of 10 ml min^kg-^, then this is equivalent to a
release of 5 ng min'^kg"'' (iv) .
PGE^ (in methanol) was diluted in saline and infused at 1 ml/min
to give infusion rates of 13 and 132 ng min~1kg~1 in Jigsaw.
Neither affected BP, nor did a bolus injection of 10 pg.
Infusion of 13 ng min~/'kg~'' and even 1310 ng min~/'kg~/' produced
no effect in Whisper. Bolus injections of 24 pg did not alter
BP and 48 pg and 240 pg produced falls of 38 and 74 mmHg respectively.
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DISCUSSION
Following partial constriction of one of the renal arteries, the
resultant mild arterial hypertension in dog is accompanied by a
transient rise in PRA and fluid retention, in agreement with
previous work (Bianchi et al, 1972), The immediate rise in BP
has been shown to be due to the rise in circulating angiotensin II
(Bianchi, Tenconi and Lucca, 1970; Bianchi et al, 1972; Miller,
Samuels, Haber and Barger, 1972; Caravaggi, Bianchi, Brown, Lever,
Morton, Powell-Jackson, Robertson and Semple, 1976). Within a
few days and in this project, by the fifth day, the renin levels
had returned to normal, despite the persistence of hypertension
(Brown, Davis and Olichney, 1966; Bianchi et al, 1970, 1972;
Harris and Ayers, 1972; Zimmerman, 1973; Miller, Samuels, Haber
and Barger, 1975). At this time, converting enzyme inhibition
and angiotensin antagonists became ineffective at lowering BP
(Miller et al, 1972, 1975; Bumpus, Sen, Smeby, Sweet, Ferrario
and Khosla, 1973).
The expansion of the vascular compartment, which reached a maximum
by the fourth day in these experiments, has been suggested to be
the cause of the elevated cardiac output seen in this model
(Bianchi et al, 1972). A similar hypertinetic circulation is
reported early in the development of hypertension in one-kidney
Goldblatt dogs (Bianchi et al, 1970; Ferrario, 1974), cellophane
perinephritic dogs (Ferrario, Page and McCubbin, 1970), one-
kidney Goldblatt rats (Ledingham and Cohen, 1962, 1964; Ledingham
and Pelling, 1967), the renoprival rat (Ledingham and Pelling,
1970) and in the Japanese SHR (Pfeffer and Frohlich, 1973). It is
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believed that the resultant everperfusion of the body leads to
"whole body autoregulation" by elevation of peripheral resistance
and that this perpetuates the hypertension as cardiac output returns
to normal (see Guyton and Coleman, 1969].
Somewhat later than the rise in PRA, which reached a maximum 2 days
after clamping, contralateral renal venous PGE and PGF concentrations
rose, reaching a peak on the fifth day. Contralateral renal venous
PGA fell in one dog (Jolly], whereas PGB rose but peaked 2 days
later than the E and F levels. Vena caval and arterial concen¬
trations of PGA and B in two other hypertensive dogs, transiently
rose? peaking at day 2 in the case of Apricot and day 5 in Flora.
In the absence of renal blood flow figures it is assumed that
these changes mirror increases in prostaglandin synthesis and
release from the kidney. Contralateral renal blood flow does
decrease acutely after clamping (flcGiff et al, 1970a; Zimmerman,
1973] due to the rise in PRA (Satoh and Zimmerman, 1975b] but
the fall is small and certainly considerably less than 50%
reduction. Since the renal venous prostaglandin concentrations
rose more than two-fold and these changes occurred as PRA
reached control levels, then it is likely that the concentration
changes were not due to dilution changes caused by flow reduction,
but are due to genuine changes in synthesis.
Angiotensin II has been shown to release prostaglandins from the
kidney (McGiff et al 1970; Aiken and Vane, 1973; Needleman et al,
1973; Danon et al, 1975] but as this is an immediate effect and
in the present experiments the plasma changes in angiotensin
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precede those of prostaglandins by about three days, then this is
unlikely.to be the mechanism of the prostaglandin release.
It is more likely that prostaglandin synthesis in the untouched
kidney is stimulated by the expansion of the vascular compartment,
secondary to the elevated PRA. There is a vast amount of evidence
implicating renal prostaglandins in fluid and salt excretion
control. Prostaglandins of the E and A series and arachidonic
acid produce natriuresis and diuresis when infused into the canine
kidney (Fulgraff et al, 1974j Tannenbaum et al, 1975) and
indomethacin depresses sodium and urine excretion (Feigen et al,
1976j Olsen et al, 197B). Injection of sodium chloride into the
renal artery of dog has been reported to release PGE (Jubiz et
al, 1976) but there are as yet no reports on the effects of
volume expansion in this species.
Prostaglandin infusions in rat also cause natriuresis, although
urine osmolality falls (Fulgraff and Meiforth, 1971) and an
essential fatty acid deficient diet (Rosenthal et al, 1974),
aspirin (Susie and Sparks, 1975) and indomethacin (Dusing et al,
1976) all prevent the excretion of a saline load.
Blood volume expansion in rat leads to a rise in plasma prosta¬
glandins, which is prevented by nephrectomy (Papanicolou, 1972,
1975) and urine prostaglandin excretion is also reported to
rise (Papanicolaou et al, 1976).
It seems plausible that the contralateral kidney responds to the
fluid retention by increasing its prostaglandin production, leading
ultimately to salt and water excretion and a return of fluid and
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electrolyte homeostasis.
Another alternative, which must be considered, is that the renal
prostaglandins are in fact natriuretic. In the conscious dog
meclofenamate and a competitive synthetase inhibitor (RO 20-5720)
cause natriuresis CKirschenbaum and Stein, 1976) and indomethacin
has been reported to cause natriuresis in the isolated canine
Kidney (Vankerweghem et al, 1975). These two observations could
explain why there is an inverse relationship between sodium intake
and peripheral plasma PGA in man CZusman et al, 1973aj Lee and
Attallah, 1974), rat (Zusman et al, 1973b) and in rabbit kidney
(Tobian, 1974). However these latter observations may be explained
by the fact that angiotensin may be causing prostaglandin release.
It is unlikely that the contralateral kidney participated in fluid
retention by increasing its prostaglandin activity since the fluid
retention preceded the rise in prostaglandin synthesis.
Unfortunately due to lack of time and insufficient results, the
effect of a prostaglandin synthetase inhibitor during the crucial
first few days after clamping could not be investigated. In
addition the prevention of the fluid retention by dialysis would
allow the hypothesis, that this causes the release of renal
prostaglandins to be tested. Investigation of this nature is
to be undertaken in this laboratory by another researcher.
There is, however, little doubt that the rise in prostaglandin
activity seen in the contralateral kidney is not a general
occurrence since there was no rise in the mixed venous blood
- 72 -
from the inferior vena cava of Flora or Apricot, despite the presence
of hypertension.
It has been demonstrated in the Goldblatt one-kidney rat that the
hypertension is accompanied by a selective expansion of the vascular
compartment, with a normal interstitial fluid volume (IFV) due to
a fall in tissue compliance. Unclipping the renal artery led to a
fall in BP and a rise in tissue compliance (Lucas and Floyer, 1974).
In the conscious dog there is a preferential retention of fluid
in the vascular compartment of anephric dogs after saline loading
compared with dogs with uninephrectomy and ureterocaval anastomosis
of the other kidney (Liard, 1976).
The possibility of a humoral mechanism of renal origin, controlling
fluid distribution, has been made. This effect may partially or
even wholly explain the antihypertensive action of the kidney.
The absence of a change in the PV/IFV ratio in the present study
may be argued as evidence that the renal control of body fluid
distribution was functioning adequately resulting in only a mild
form of hypertension. If this were so, then the greatest demand
on the kidney would be when fluid retention was at its peak. At
this time prostaglandin output is also elevated to its maximum.
Using the data of Bianchi et al (1970j 1972), there was found to
be no change in the PV/IFV ratio in the two-kidney dog, but a
large prolonged increase was present in the one-kidney dog. This
strongly suggests that the presence of normal, but not necessarily
excreting renal tissue, does affect fluid distribution and in the
direction required by the antihypertensive kidney theory.
- 73 -
The pulmonary, barrier to PGE Cand PGF) (Vane and Ferreira, 1967;
Robertson, 1975) should prevent extrarenal effects, unless of
course the metabolites are bio-active. The efficiency of this
barrier was not reduced in these hypertensive dogs since PGE2
infusions as high as 260 times the calculated peak release from
the untouched kidney, failed to acutely alter BP. In addition
indomethacin failed to alter BP in the normotensive and hyper¬
tensive dog. To date, only one successful report of chronic
administration of indomethacin producing chronic hypertension
has appeared (Colina-Chourio et al, 1975). Fiowever, another
group has failed to demonstrate this using the same species,
rabbit (Muirhead et al, 1976).
Prostaglandin of the A and C series would not be hindered by the
pulmonary barrier, however. The few results presented of PGA,
show a rise in circulating PGA which, in view of its stability in
the pulmonary circulation, has been suggested as a circulating
hormone. Consequently, it might be suggested that PGA could
affect various parts of the cardiovascular system and be responsible
for the distribution of the extracellular fluid.
The levels of PGA reported are in the subnanogram and nanogram
per ml level. Using the data of Fulgraff et al (1974), McClatchey
and Cam. (1973) and Tannenbaum et al (1975), these are pharmacological
levels of PGA, producing natriuresis and increasing blood flow of
the kidney.
However, in view of the scepticism regarding the natural existence
of PGA and the fact that the PGA antibodies main cross reaction is
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with PGB2 at 100%, then it would be more cautious to think of the
reported PGA levels in terms of immunoreactive PGA.
In one case where the clamped kidney was sampled, a very rapid rise
then fall of prostaglandin renal venous concentrations was recorded,
within two days of clamping. In the absence of RBF data "the results
are difficult to interpret since RBF would be expected to fall due
to clamping (Bounous and Shumacker, 1962; Lupu, Maxwell, Kaufman
and White, 1972; Flarris and Ayers, 1972; Ferrario and McCubbin,
1973] and this would raise renal venous concentrations.
Chronically, RBF does return to control again [Corcoran and Page,
1942; Bounous and'Shumacker, 1962] but it is not known how rapidly
this occurs in the two-kidney Goldblatt dog. In the one-kidney
Goldblatt dog up to 7 days are required [Ferrario and McCubbin,
1973].
McGiff et al (1970] and Herbaczynska-Cedro and Vane [1973] believe
that acute renal ischaemia causes prostaglandin release from that
kidney. However, taking into account the fall in RBF, Beckman and
Zehr [1975] found a fall in release, although in agreement with the
previous two groups, they found a rise in concentrations in the
renal venous blood. Moreoever, Gross, Mujovic, Jubiz and Fisher
[1976a] produced a 12 hr long 30% reduction in RBF in the
anaesthetised dog and found that the renal venous PGE concentration
rose slowly to 200% of control by the 8th hour. This is not an
increase in synthesis as the authors suggest since there was no
immediate tripling of concentration, but is a depression of synthesis
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with a slow recovery, reaching 66% of control by the 8th hour.
Irrespective of whether prostaglandin synthesis in the ischaemic
kidney does fall, it is probable that intrarenal prostaglandin
concentrations rise at certain sites and this probably attenuates
the vasoconstrictor and antidiuretic activities of angiotensin
in the kidney (Aiken and Vane, 1973).
According to Satoh and Zimmerman (1975a), the elevated angiotensin
activity during renal ischaemia causes a rise in intrarenal
prostaglandin activity and since angiotensin I (Needleman et al,
1973) and angiotensin II (McGiff et al, 1970a; Needleman et al,
1973) both release renal prostaglandins, then this may explain
this observation in the ischaemic kidney.
PGA^ has been shown to antagonise the excretory changes produced
by acute renal artery stenosis in the dog (McClatchey and Cam,
1973), whilst in the chronically ischaemic canine kidney, PGE2
and PGA^ both reduce the disturbances caused by the stenosis, with
the exception that renin release is further activated (Varkarakis,
Szolnoky and Murphy, 1975). The rise in intrarenal prostaglandin
concentrations in the ischaemic kidneys of our dogs was therefore
most likely beneficial to the function of this kidney.
The selective rise in PGE seen in the dog Acorn, 1 day after the
loss of 50% of her blood volume, supports the findings of Collier,
Herman and Vane (1973), that hypotensive shock causes the release
of renal prostaglandins. According to Johnston and Selkurt (1976),
however, there is not a release of renal PGE after the haemorrhage
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but only after reinfusion.
Gross et al (1976a) have shown that the changes in renal venous PGE
in dog after prolonged renal ischaemia, parallel the erythropoietic
activity and that indomethacin abolishes the activity of both. In
addition, PGA£ and but not F^oc when given to mice and canine
kidneys stimulated erythropoiesis (Gross, Brookins, Fink and
Fisher, 1976b).
In conclusion, in the two-kidney Goldblatt dog there is a transient
rise in prostaglandin production by the untouched kidney, probably
in response to the fluid retention, resulting in diuresis. There
is also a possibility that the prostaglandins (possibly of the A
series) maintain the distribution of the body fluids, thus helping
to contain the hypertension. Whilst nothing can be stated about
the rate of synthesis in the clamped kidney, the very early transient
rise in renal venous PGE concentrations of this kidney, probably
mirrors a raised intrarenal concentration, which will protect the
kidney against the renal artery stenosis.
SECTION II
RENAL PROSTAGLANDINS IN EXPERIMENTAL
RENAL HYPERTENSION IN RATS
- 77 -
METHODS
One hundred and thirty-six male and female Wistar rats, of approximately
similar size and fed on a standard laboratory diet, with water ad lib,
were divided into seven experimental groups, 30 rats serving as controls.
Renal hypertension was induced by clipping the left re.nal artery with a
small silver clip (first operation] and in some rats, clipping the right
renal artery (second operation) two weeks later. The rats were killed
at various stages after clipping as follows:
Group 1-20 rats killed one week after the first operation.
Group 2-20 rats killed two weeks after the first operation.
Group 3-20 rats killed three weeks after the first operation.
Group 4-20 rats killed four weeks after the first operation.
Group 5-20 rats killed one week after the second operation.
Group 6-20 rats killed two weeks after the second operation.
Group 7-16 rats killed ten weeks after the second operation. (The
chronic hypertensive group).
The rats were weighed weekly and arterial blood pressure was measured by




From each group, six to eight rats were used for the estimation of
bilateral renal function, namely renal plasma flow (RPF] and glomerular
filtration rate (GFR] and the remaining rats were used for the
estimation of renal venous PG concentrations.
RPF and GFR were estimated by means of the clearances of PAH and of
inulin respectively. The rats were anaesthetised with pentobarbitone
(40 mg/kg i.p.) and tracheotomized. The left subclavian vein was
catheterised for the infusion of the clearance solution at a rate of
0.05 ml/minute using a motor driven syringe (Braun]. The clearance
solution was composed of 1% inulin, 1% PAH and 2% Na^SO^. dissolved
in 0.9% saline and buffered to pH 7.4 with bicarbonate.
Both ureters were catheterised after the method of Mercer (1971] and
a ten minute urine sample was collected from each ureter 50 minutes
after the infusion had begun. After heparinisation (1000 U/kg], blood
samples (0.5 ml] were removed from a carotid artery catheter 50 and
60 minutes after the initiation of the infusion, for the calculation
of mean plasma PAH and inulin concentrations, which we tried to hold
at about 7 and 30 mg% respectively.
The blood was centrifuged in Eppendorf tubes and 0.2 ml of plasma
removed and subjected to plasma protein precipitation using Somogyi
reagent. The urine was carefully transferred to a volumetric flask
and diluted to 100 ml. Diluted urine and protein-free plasma were
analysed for inulin and PAH using a resorcinol method for the former
N (1-napthyl]-ethylene diamine as a coupling reagent for the latter
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and both were compared with standard solutions in a spectrophotometer
(Bausch and Lomb, SP 20, USA).
The clearances of PAH and inulin were calculated and expressed in terms
of body weight. The extraction ratio for PAH was not taken into
account. Girndt and Ochwadt (1969) have shown that four weeks after
clamping a renal artery, PAH extraction was unaltered in both the clamped
and the contralateral kidneys (0.84 approximately).
Prostaglandin Estimation
Blood samples for the estimation of prostaglandins were drawn from
the renal veins of anaesthetised rats after a midline laparotomy and
catheterisation of the inferior vena cava. Within each group, the
left and right renal venous samples were pooled separately (final
volume of about 10 ml).
A known amount of deuterium labelled prostaglandin, 1 ug d^ PGE^ and
500 ng PGF^^were added to each sample immediately before the plasma
prostaglandins were extracted and subjected to silicic acid column
chromatography. The plasma was acidified to pH 4 with hydrochloric
acid and partitioned three times with two volumes of ethyl acetate.
The combined ethyl acetate fractions were washed with 0.1 volumes of
water and evaporated to dryness. The residue was dissolved in 20 ml
67% ethanol and washed twice with 20 ml petroleum spirit and evaporated
to dryness. The extract was dissolved in 0.5 ml 30% ethyl acetate in
toluene and the PGE^ and PGF^^were separated using silicic acid
chromatography (Poyser, 1972).
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The extracted PGE„ and PGF„ were converted to methyl ester/methoxime/2 2 °<
TMS and methyl ester/TMS derivatives respectively using the methods
of Thompson, Los and Horton (1970), and Blatchley, Donovan, Horton and
Poyser (1972).
Using combined gas chromatography - mass spectrometry (GCLIS), with a
multiple ion detection system (Finnigan 30000 quadrupole mass
spectrometer), the ratio of protium to deuterium peaks of each prosta¬
glandin derivative was obtained and compared with a standard calibration
over the range 1 to 1000 ng of protium (Hensby and Naylor, 1974). The
m/e peaks for the protiated PGE^ and PGF^ were 295 and 423 and those
used for the deuterated PGE„ and PGF„ were 299 and 427 respectively.
Z Z o<-
The column used in the GC was 1 m long and 2 mm in bore containing
3% 0V1 on silanised Supelco. The carrier gas flow was adjusted to 30 ml
minute ^ and the column temperature held at 230°C.
Apart from allowing the absolute amount of prostaglandin to be
calculated by isotope dilution, the addition of the deuterated
prostaglandins prior to extraction allowed the recoveries to be
estimated. The recovery for PGE„ was about 65% and that for PGF '2 2
was about 68% and the reported levels were corrected for recovery.
Statistical analysis of the results was performed by the Student
two-tailed t test, except for the renal function results, where a
one-tailed t test was used. Values are expressed as mean ± s.e. and
only probabilities less than 0.05 were accepted as being statistically
significant.
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Table 5: Systolic Blood Pressure and Renal Venous PGE and PGF
— z
Concentrations
Group N Systolic Diastolic
pge2 PGF2«
Left Right Left Right
Control 30 126 ± 2.7 100 ± 2.6 4.0 3.8 2.7 2.2




4.4 2.7 3.7 2.1




5.6 3.6 4.3 2.7




4.6 2.6 3.2 2.0




3.2 5.0 1 .2 2.9




3.0 4.5 1.6 4.4




4.7 6.2 2.7 3.1




2.9 4.5 1.9 3.3
Blood pressures are in mmHg, PGE^ and PGF2ciu6 concentrations
-1
are expressed in ng ml
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Control 30 257 ± 12 32.4 ± 0.6 35.2 ± 0.5 35.9 ± 0.6











































Average organ weight ratios. Ratios are expressed x 10




□ne week after the production of renal ischaemia (groups 1 to 4),
there was a significant rise in blood pressure, which reached a peak
by the third week (group 3). Systolic blood pressure rose from
126 i 2.73 mmHg to 148 - 5.13 mmHg (P < 0.001) and diastolic pressure
increased from 100 ± 2.55 mmHg to 123 i 4.26 mmHg (P < 0.001) three
weeks after clamping (group 3). See Table 5.
Cardiac hypertrophy also occurred over this period as seen by the rise
in the heart/body weight ratio (Table 6). The left kidney/body weight
ratio rose in group 1 rats but fell in group 2 and was not significantly
different from control in later groups. The right kidney hypertrophied
in each of the unilaterally clamped groups, except for group 2 (Table 6).
An inverse relationship between renal mass and the level of systemic
hypertension was noted in almost all cases.
During ischaemia of the right kidney, as well as the left (groups 5,
6 and 7), systolic and diastolic pressures rose further, within the
range 126/100 to 183/150 mmHg ten weeks after the second operation
(the chronic hypertensive group).
The right kidney, which had previously been hypertrophied before the
second operation, was now not significantly different from control.
Cardiac hypertrophy was very marked in these bilaterally ischaemic rats.
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Table 7: Renal Plasma Flow
Group N
Left Kidney Right Kidney
-1 -1
ml min Kg i • "1 -1ml nun g
-1 -1
ml min Kg ml mm g
Control 10 8.23 ± 1.29 2.39 ± 0.39 9.12 ± 1.31 2.48 ± 0.37
1 8 B.34 ± 1.32 1.57 ±0.23 10.14 ± 1.25 2.62 ± 0.36
ns ns ns ns








3 8 7.46 ± 1.12 2.11 ± 0.36 9.00 ± 1.39 2.52 ± 0.36
ns ns ns ns
4 8 7.59 ± 0.35 2.07 ± 0.12 10.95 ± 2.25 2.62 ± 0.53
ns ns ns ns
5 8 5.85 ± 0.95 1.83 ± 0.28 7.14 ± 0.89 2.01 ± 0.27
ns ns ns ns








7 6 5.49 ± 0.79 1.86 ± 0.20 6.30 ± 0.75 1.92 ± 0.16
ns ns ns ns
-1 -1
RPF expressed relative to bodyweight [ml min Kg ) and kidney
-1 -1
weight [ml min g ).
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Renal Function Changes
After unilateral renal ischaemia, RPF of the clamped Kidney fell
significantly two weeks after clamping (group 2), from 8.23 ± 1.28 ml
-1 -1 -1 -1
min Kg to 4.28 t 1.55 ml min Kg (P < 0.05) and subsequently
rose again to control values (Table 7). The contralateral Kidney
showed no significant change in RPF at the time. Due to the well
maintained GFR, the filtration fraction (FF) rose significantly only
in the ischaemic Kidneys of group 2 rats (Table 8).
On clamping the right Kidney, RPF fell two weeks later in group 6
from 9.12 ± 1.31 ml min ^ Kg ^ to 3.43 - 0.25 ml min ^ Kg ^ (P < 0.025)
(Table 7). Left RPF also fell, from 8.23 ± 1.29 ml min ^ Kg ^ to
-1-1
4.44 ± 0.44 ml min Kg (P < 0.025). This fall was also significant
(P < 0.0005) when compared with group 4, which had undergone exactly
the same procedures and time course, except for the second operation.
As GFR was so well maintained, FF rose in the left Kidneys of group 6.
In group 7, the chronic hypertensive group, no difference was detected
between either Kidney and control.
PGE„ and PGF„ _Renal Venous Concentrations2 2<*
After the first operation, left renal venous PGE^ and PGF^o<
concentrations were higher than control, whereas the concentrations
in the right renal venous plasma were similar or slightly lower than
control, except for group 4. See Table 5, groups 1 to 4.
After the second operation, PGE^ and PGF^,* concentrations rose in
the right renal venous plasma one week later (group 5).
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Table 8: Glomerular Filtration Rate
Group N






ml min kg t . -1 -1ml min g
Control 10 1.80 ± 0.25 0.52 ± 0.07 2.20 ± 0.28 0.59 ± 0.07
















3 8 - - - _


































GFR expressed relative to bodyweight (ml min Kg ) and kidney
-1-1
weight (ml min g ).
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ure 15: Correlation between PGE^ and PGF^^ from the renal
venous blood of the hypertensive rats and control
rats. The 95% confidence limr'ts are shown.
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By the second week [group 6), PGE^ had risen even more in the right
renal venous plasma but PGF^ot had fallen, although still above control.
Both PG s rose transiently in the left renal venous plasma. In the
chronic hypertensive rats [group 7), right renal venous PGE^ and PGF^oc
concentrations were higher than control, in contrast to the left renal
venous concentrations, which were lower than control.
A good correlation was found between the PGE^ and PGF^c* concentrations,
with a ratio of about 1.6 for PGE^/PGF^c* [Figure 15).
The PGE^ concentrations showed a very good inverse correlation with
the renal plasma flow for both kidneys (Figures 16 and 17) suggesting
that the concentration changes were partially if not wholly due to
the flow changes. No significant correlation was seen with PGF^^.
Prostaglandin Secretion Rates
I
Secretion rate of each PG may be calculated from the product of the
total mean RPF and the PG concentration for each group since PG s
appear to be released on synthesis [Anggard, Bohman, Griffin, Larsson
and Maunsbach, 1972). This assumes that all the arterial PG s presented
to the kidney are cleared in one passage because of the high activity
of the metabolising enzyme, 15 hydroxy PG dehydrogenase, in the renal
0
cortex (Anggard, Larsson and Samuelsson, 1971). The clamped kidney
shows a fall in secretion rate of PGE^ from 8.68 ng/minute to 6.24,
5.57, 8.51 and 4.84 ng/minute in groups 1, 2, 3, and 4, respectively.
PGF^,* secretion rate also fell, from 5.86 ng/minute to 5.25, 4.28,
5.92 and 1.81 ng/minute in each of the above respective groups.
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See Table 9. The contralateral Kidney of these groups showed no
change in secretion rate of either PG. After ischaemia of the right
Kidney, secretion rate of both PG s began to fall in the right Kidney
and continued falling in the left Kidney (groups 5 and 6). A subnormal
secretion rate of both PG s existed in the two Kidneys of the chronic





y = Zf.78 X + 1.58
r = 0.67 ; P< 0.01
, . . -1 -1x-1(ml ram g )
Figure 16: Relationship between the left (x) and right (•) renal
venous PGE and the reciprocal of the respective renal
-1-1



























































Figure 17: Systolic and diastolic blood pressures (mmHg), renal
venous PGE^ concentrations of the left (► •) and
right (• •) Kidneys and RPF and GFR of both Kidneys
[the left and right respectively in each pair] at
different stages of hypertension. GFR in blacK bars
and RPF in white bars.
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Table 9: Calculated PG Secretion Rates
Group
PGE2 PGF„ .2o7
Left Kidney Right Kidney Left Kidney Right Kidney
Control 8. 68 8.71 5.86 5.04
1 6.24 6. 83 5.25 5.31
2 5.57* 8. 06 4.28* 6. 05
3 8. 51 6. 65 5.93 5.11
4 4.84 11.41 1.81 6.62
. 5 5. 62 9.25 2.64 9.04
6
i
4.13* 5.51* 2.37* 2.75*
7 3. 08 6.67 2.02 4.81
Calculated PG secretion rates (ng/min) obtained from the product of
the PG concentration and the total mean RPF of each respective group.




Four weeks after clamping a renal artery, the resultant hypertension
was associated with normal PAH and inulin clearances in both the clamped
and the contralateral kidneys of rat. However, the medullary blood
flow of the contralateral kidney was elevated (Girndt and Ochwadt,
1969).
Our findings are in agreement since only a transient fall in PAH
clearance was seen two weeks after clipping, but by the fourth week,
the renal clearances were normal.
At variance to this, Kramer and Ochwadt (1974) report that rat kidneys
clipped six to ten weeks previously had lower PAH and inulin clearances
than the contralateral kidneys, but this was probably due to the
dehydration and ADH infusion, which these rats underwent.
We have demonstrated that there is a rise in renal venous prostaglandin
E^ and concentrations from the clipped kidney, the other kidney
showing no change. The correlation between the PGE^ concentrations
and the reciprocal of renal plasma flow (RPF) suggests that these
concentration changes are not due to increased output, but are more
likely due to the dilution effect of flow changes. Indeed, the
calculated secretion rates of both prostaglandins in the clipped kidney
falls with the progression of hypertension, whilst the secretion in the
contralateral kidney does not change.
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It should be realised that there are a number of assumptions made in
calculating secretion rate. The Kidney must clear all the arterial
prostaglandins presented to it and it should release immediately on
synthesis, without storing. Prostaglandins are believed to be released
on synthesis (see McGiff and Nasjletti, 1973) and the kidney removes
80 to 90% of blood borne PGE^ (Aiken and Vane, 1973) and almost all
of PGA^ in a single passage (Attallah, Payakkapan and Lee, 1974), due
to the very high activity of 15 hydroxy prostaglandin dehydrogenase
° u
in the renal cortex (Anggard, Larsson and Samuelsson, 1971).
Reduced release of PGE-like material has been demonstrated in the
isolated perfused kidney of the one-kidney Goldblatt rat (Leary,
Ledingham and Vane, 1974) and in the incubated renal medulla from the
clipped kidneys of the one and two kidney Goldblatt rats and from the
Japanese spontaneously hypertensive rats (SHR), the depression being
related to blood pressure (Sirvios and Gagnon, 1974). According to
Pugsley, Beilin and Peto (1975) the synthetic capacity of both the
clipped and the contralateral kidneys of Goldblatt rat is reduced
equally by about 30% when assayed by combined GCMS.
In contrast a rise in renal immunoreactive PGE concentration is reported
in the clipped kidneys of chronically hypertensive rat (Jaffe, Parker,
Marshall and Needleman, 1972).
During the acute phase of hypertension an increased PGE-like concentration
was seen in the clipped kidney but decreased in the chronic stages
(after three months) (Somova, 1971 and 1973).
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"Post-salt" hypertensive rat Kidneys have elevated PGE-like concentration
(Tobian and Azar, 1971) and PGA levels are greater than control in the
Kidneys of SHR (Zusman, Spector, Caldwell, Speroff, Schneider and
Mulrow, 1973a).
Evidence from osmophilic renal interstitial cell (RICs granule counts
also suggest increased prostaglandin synthesis. Decreased granule count
is reported in the Kidneys of SHR (Mandal, Frohlich, Chrysant, Pfeffer
and Nordquvist, 1973), "post-salt" rats (Tobian, Ishii and Duke, 1969)
and in various hypertensive rat models (Muercke, Mandal and Violini,
1970). The untouched Kidney shows a greater reduction than the
clipped Kidney and the reduction is related to the blood pressure
(Ishii and Tobian, 1969).
Work in rabbits suggests that a decrease in lipid granule count is
due to an increase in prostaglandin precursor turnover (Comai, Prose,
Farber and Paulsmed, 1974).
The renal prostaglandins are proposed as having a natriuretic function
and to protect the Kidney against the vasoconstrictor/antidiuretic
influence of the renin and sympathetic system (McGiff and Nasjletti,
1973 and Lonigro, Terragno, Malik and McGiff, 1973). However, in the
rat Kidney, unlike that of other species, PGA^ and PGE^ potentiate
the effect of renal nerve stimulation and at higher doses actually
cause vasoconstriction as does PGF^ (Malik and McGiff, 1975). In
the New Zealand genetically hypertensive rat a deficiency of 15 hydroxy
prostaglandin mediated potentiation of intrarenal noradrenaline vaso¬
constriction. This defect might well be the cause of hypertension in
these rats (Armstrong, Blackwell, Flower, McGiff, Mullane and Vane, 1976).
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The inverse relationship between PGE^ concentration and RPF, which
we found might well be due to prostaglandin potentiation of
vasoconstrictors.
PGE^ is natriuretic in the rat kidney and micropuncture studies suggest
that the distal tubule is the site of sodium reabsorption inhibition
it
(Fulgraff and Fleiforth, 1971) and increased blood (Papanicolaou, 1972
and 1975) and urinary output (Papanicolauo, Flountokalakis, Safar,
Sostirpoulou, Bariety and Flilliez, 1976) of prostaglandins are reported
after fluid loading in rats. The diuresis seen after saline loading
is prevented by essential fatty acid diet (Rosenthal, Simon and
Silbergleit, 1974) , aspirin (Susie and Sparks, 1975) and by indomethacin
(Dusing, Fielder and Kramer, 1976).
Fiowever, arachidonic acid prevents excretion of a saline load in rat
(Weber, Holzgreve, Stephan and Flerbst, 1975).
Despite an increased BP, the blood flow and GFR of the untouched
kidney are approximately normal, yet this kidney excretes twice the
normal amount and two-thirds of the total sodium excreted (Kramer and
Ochwadt, 1974) probably due to reduced reabsorption in the ascending
/
loop of Flenle of the superficial nephrone (Stumpe, Lowitz and Ochwadt,
1970).
A rise in inner cortical and medullary blood flow is seen in this
kidney, associated with a dissipation of the medullary solute gradient
(Girndt and Ochwadt, 1969). Juxtamedullary GFR is doubled, resulting
in a small increase in total GFR (Stumpe, Lowitz, and Ochwadt, 1969).
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It is possible that the renal pi-ostaglandins may account for these
changes since they are natriuretic and indomethacin does reduce
medullary blood flow in this species (Solez, Fox, Miller and Heptinstall,
1974). The fact that PGE^ behaves differently on the renal vasculature
in rat in comparison to other species does complicate interpretation
of all the observed effects (Malik and McGiff, 1975 and Armstrong et
al, 1976).
In addition we observed no change in renal venous concentration or
secretion rate of either prostaglandin in the untouched kidney, but
this does not remove the possibility that at certain sites within the
kidney, prostaglandin concentrations may have been altered.
The increase renal venous prostaglandin concentrations in the clipped
kidney, which must reflect increased intrarenal concentrations, only
makes matters worse in this kidney because of potentiation of intra¬
renal vasoconstriction. However, the decrease in calculated secretion
rate by this kidney may attenuate the effect of this mechanism.
The rat kidney does have antihypertensive properties, independent of
urine loss, when introduced into the circulation of an hypertensive
rat (Tobian, Schonning and Seefeldt, 1964). This property is also
shared by implants of renal medulla from normal rats (Manthorpe, 1973),
"post-salt" rats (Tobian and Azar, 1971) and cultures of RIC s
(Muirhead, Germain, Leach, Brooks and Stephenson, 1973). The renal
medulla from nomotensive rats is antihypertensive when transferred
into SHR (Weiss, Manger, Praag, Hart, Hulse and Soss, 1976).
Curiously, however, the medulla from the clipped kidney is more
potent than that from normal kidney and untouched kidney, exposed to
the high BP has very little antihypertensive action (lianthorpe, 1973).
Prostaglandins are probably not the mediators of the renal endocrine
antihypertensive property in this species although there is little
doubt that prostaglandins of the E and A series are antihypertensive
in this species (Somova, 1972; Wendling, Ducharme and Graham, 1972;
Muirhead, Leach, Brown, Daniels and Hinman, 1967; Leach, Armstrong,
Germain and Muirhead, 1971, and McQueen and Bell, 1976). Indomethacin
fails to prevent the antihypertensive action of medullary implants
(Manthorpe, 1975) and the extracted lipids from RIC cultures incubated
in indomethacin are still effective antihypertensive material
(Muirhead, Leach, Germain, Byers and Armstrong, 1974).
As far as PGE2 is concerned, our results confirm this finding, since
there was not an increase in the secretion rate in either kidney.
We did not study PGA in this project and this is the prostaglandin
most likely to have an extrarenal effect, since it can escape pulmonary
degradation. However, it has been show that the rat lung is not as
efficient as the dog lung at removing circulating PGE since a 35%
removal is reported (Papanicolaou and Meyer, 1972) as compared with
about 95% in dog (Ferreira and Vane, 1967, and Robertson, 1975).
SECTION III
RENAL PROSTAGLANDINS IN RENAL BLOOD FLOW




Ten mongrel dogs of either sex, weighing between 8 and 15.5 Kg were
used. After induction of anaesthesia (pentobarbitone, 30 mg/kg i.v.)
the animal was tracheotomized and systemic blood pressure was measured
from the left femoral artery. Temperature was held at 37°C by a
heating pad controlled by a thermistor rectal probe. A midline
laparotomy was performed and a catheter placed in the left renal vein
via a femoral vein, for renal venous blood sampling. The left ovarian
or spermatic vein was ligated. Hypotonic (0.8%) saline was infused
intravenously at about 2 ml/minute to ensure adequate urine flow. The
animal was heparinised (1000 U/kg) and blood removed from the right
carotid artery by a slowly revolving Watson Marlow MHRE pump. Part
of this flow passed through a cannulating flow probe (Statham, 2.00 mm
lumen) and was carried by silicone tubing through a stab wound in the
abdominal wall to the catheterised left renal artery. Renal artery
pressure (RAP) was measured at the tip of this catheter through a fine
tube.
The remaining flow was shunted through a Starling resistance to a
femoral vein. Using compressed air, with a controllable leak, the
pressure in the Starling resistance box and so the perfusion pressure
of the kidney, could be controlled.
Using this system the kidney could be perfused at constant pressure
with the pump at a constant slow speed, thus preventing possible
damage to the blood at high pump speeds.
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All pressures were measured using Consolidated Electrodynamic L223
transducers and the electronically averaged pressures and renal blood
flow signals were recorded on light sensitive paper (Honeywell,
Visicorder, 22061. Pressure flow curves were obtained by varying
RAP every five minutes, since autoregulation was complete within three
minutes. After a control curve was obtained, meclofenamate (10 mg/kg
i.v.) dissolved in 10 ml of 0.9% saline was injected and after 15 to
20 minutes another pressure flow curve was recorded.
10 ml samples of renal venous blood were removed at 50, 100, 150 and
200 mmHg during the determination of control pressure flow curve and
at two pressures after meclofenamate in four experiments. The samples
were collected in ice cold centrifuge tubes and spun at 4°C for 25
minutes at 15,000 g. The haematocrit of each sample was noted for
estimation of renal plasma flow and so prostaglandin secretion rate.
The plasma was stored in a freezer for less than three weeks before
the assay. The plasma was assayed for prostaglandins by radioimmuno¬
assay as previously described in Section I.
Pressure-Flow Curve Fitting
The pressure-flow curves were plotted for each individual experiment
and the best curve fitted by eye. In order to be objective, the data
were also fitted by computer to a cubic expression, which describes
the general shape of the autoregulation curve.
3
y = p + q (x - m) + r (x - m)
where p is the flow during autoregulation (point of inflexion]
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m is the pressure at this point
q is the slope of the plateau part of the autoregulation curve
r is a constant
x is the pressure at any point
and y is the flow at any point.
Figure 18 demonstrates the results of one experiment [experiment 7)
to which the cubic expression has been fitted by the computer using
the method of least squares.
A straight regression line was also fitted to the experimental point.
In the absence of autoregulation, the plateau gradient (q) would
approximate to the regression coefficient (g) such that q/g would
tend to unity. Values of q/g less than one or even negative were
taken as objective evidence for autoregulation.
Values are expressed as means - s.e. and the results were analysed
using the students 't' test; probabilities less than 5% were accepted
as being statistically significant.
. . ■ J! »
50 100 150 200 250
RAP rnmHg
Figure 18: This figure shows the individual results of one experiment
(experiment 7) before (•) and after (o) meclofenamate.
The lines through the points were obtained from the cubic
expression of each set of points: y = 24.9 + OQ40 (x - 141] +
3
5.26 (x - 141) for control and y = 18.5 + 0.037 (x - 137) +
3
6.46 (x - 137) for the meclofenamate curve.
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RESULTS
Two experiments showed no autoregulation and a third lost autoregulation
before completion of the control period. In the remaining seven
experiments autoregulation was obtained, dean autoregulation flow was
54 ± 13 ml/minute (n = 7) and meclofenamate C10 mg/Kg i.v.] reduced it
to 26 ± B ml/minute (n = 6, P < 0.05). Autoregulation was lost in one
experiment after meclofenamate. The mean autoregulation flow corrected
-1
for Kidney weight was 1.6 ± 0.4 ml min per gm kidney, which is about
30% lower than that reported by Ono, Kotubin and Hashimoto (1974).
Midpoint autoregulation pressure (m) did not change after meclofenamate,
133 i 5 mmHg before and 144 - 10 mmHg after. The ratio q/B was always
less than unity before and after meclofenamate (except in one experiment
where autoregulation was lost after meclofenamate) indicating preservation
of autoregulation. See Table 10 for the haemodynamic data.
Prostaglandin Concentration
There was a tendency for renal venous PGE concentrations to rise and
calculated secretion rates (the product of the concentrations and their
respective renal plasma flows) to fall as RAP was reduced. Using
absolute values no significance could be demonstrated due to the large
variation in values between experiments as is evidenced by the large
standard errors. See Table 11. Individual experimental results are
shown in Table M.
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Table 10: Renal Haemodynamics Before and After Meclofenamate
Experiment m q B P q/B
1A 116 0.012 0.076 29.2 0.158
1B 132 0.057 0.095 13.4 0.600
2A 133 -0.027 0.036 25.4 -0.750
2B 184 0.025 0.033 10.7 0.757
3A 120 0.016 0.180 33.9 0.089
3B 155 0.147 0.175 25.9 0.840
4A 150 0.070 0.360 73.0 0.194
4B 113 0.111 9.229 41.5 0.484
5A 145 0.059 0. 538 112.7 0.110
5B 144 0.048 0.130 46.3 0.369
6A 127 0.060 0.261 80.8 0.229
6B (42) (0.24) 0.17 (6.97) (1.43)
7A 141 0.040 0.080 24.9 0. 560
7B 137 0.037 0.083 18.5 0.446
A - Control Values
B - Values after Meclofenamate
m = autoregulation midpoint pressure (mmHg)
q = slope of autoregulation point of curve
B = linear regression coefficient
p = is the autoregulation flow (ml/min)
q/B = is an index of autoregulation. In the absence of
autoregulation this value tends to unity.
In experiment 6 autoregulation was lost after meclofenamate, the
pressure-flow curve becoming virtually rectilinear. The derived
parameters except B have little meaning.
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By expressing the values at 50, 100 and 150 mmHg as ratios of those
at 200 mmHg, a statistically significant rise in concentration of
PGE was seen at the lowest pressure of 50 mmHg (P < 0.05) and
calculated secretion rate fell (P < 0.01).
PGF concentrations expressed in a similar manner also rose as pressure
fell, reaching statistical significance at the lowest pressure
(P < 0.05). The rise in PGF concentration paralleled the rise in
PGE concentration as shown by the excellent correlation over a wider
range of concentration O = 0.85, P < 0.001) in Figure 19. Unlike
PGE secretion, PGF secretion did not change.
Meclofenamate (10 mg/kg) produced a significant fall in the calculated
secretion rate of PGE at pressures of 100 and 150 mmHg from 15.65 ±
4.43 ng/min (n = 8) to 3.61 ± 0.61 ng/min (n = 8, P < 0.05). Renal
venous plasma concentration also fell, from 315 ± 58 pg/ml to
178 ± 26 pg/ml (P < 0.05). PGF showed similar response, with a
fall in the secretion rate from 18.93 ± 5.44 ng/min (n = 7) to
2.73 ± 0.27 ng/min (n = 7, P < 0.01) and in concentration from
314 ± 57 pg/ml to 134 ± 23 pg/ml (P < 0.01).
- 106 -
Table 11: Prostaglandin Concentrations (pg/ml) and Calculated
Secretion Rates (ng/min) in Absolute Values and in
Ratios Relative to the Values at 200 mmHg
RAP
N






50 6 542 ± 222 11.31 ± 4.83
100 6 311 ± 47 10.77 ± 2.91
150 5 398 ± 127 19.47 ± 7.71
200 6 360 ± 110 '15.99 ± 4.63
Ratios Ratios
50 6 1.40 ± 0.17* 0.65 ± 0.12+
100 6 1.11 ± 0.25 0.86 ± 0.21
150 5 1.04 ± 0.17 0.97 ± 0.25
200 6 1.00 1 .00





50 4 800 ± 353 17.53 ± 7.24
100 4 237 ± 67 10.79 ± 3.84
150 4 363 ± 105 25.20 ± 9.07
200 4 368 ± 173 16.37 ± 5.62
Ratios Ratios
50 4 *CD^ra+i<3*C\lCN 1.04 ± 0.18
100 4 1.07 ± 0.33 0.92 ± 0.30
150 4 1.33 ± 0.47 1.82 ± 0.72
200 4 1.00 1 .00
* P < 0.05 1 P < 0.01
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DISCUSSION
Acute renal ischaemia increases the concentration of PGE-like material
in the renal venous blood of the canine kidney (McGiff, Crowshaw,
Terragno, Lonigro, Strand, Williamson, Lee and Ng, 1970a). Herbaczynska-
Cedro and Vane (1973) confirmed this in the pump-perfused canine kidney
and indomethacin (1 - 10 mg/kg i.v.) prevented both the rise in
concentration of PGE-like substance and the autoregulation of blood
flow. It was suggested that the kidney releases PGE^ in response to
lowered renal artery pressure (RAP) and that this mediates the fall
in renal vascular resistance, resulting in the autoregulation phenomenon.
Using essentially the same approach, we still obtained autoregulation
in six our of seven experiments after meclofenamate (10 mg/kg i.v.)
despite a 70% fall in prostaglandin synthesis.
In the naturally perfused kidney of anaesthetised dog, prostaglandin
synthetase inhibitors fail to abolish autoregulation (Owen, Ehrhart,
Weidner, Scott and Haddy, 1975; Venuto, O'Dorisio, Ferris and Stein,
1975; and Anderson, Taher, Cronin, McDonald and Schrier, 1975b). The
latter two groups suggest that the pump-perfused kidney may show
prostaglandin dependent autoregulation due to the high resting
resistance seen in this preparation. This cannot be so since we also
had high resistance preparations yet still maintained autoregulation
after inhibition of prostaglandin synthesis.
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lire 19: Correlation between the renal venous PGE^ and the PGF^oc
concentrations during the acute autoregulation experiments.
The 95% confidence limits are also shown.
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J
It is possible that despite 70% inhibition of synthesis (a figure
in agreement with Venuto et al, 1975], the smaller fall in renal venous
and so probably of intrarenal prostaglandin concentration, due to the
concomitant fall in blood flow, may not have been sufficient to
abolish autoregulation.
In agreement with Herbaczynska-Cedro and Vane (1973] and McGiff et al
(1970a], we did obtain a rise in PGE concentration when flow was
reduced below the autoregulation range (less than 80 mmhig]. However,
as the percentage flow reduction was greater than the percentage increase
in PGE concentration, secretion rate must have fallen. Calculated
secretion rate of PGE did fall significantly reaching statistical
significance at 50 mmHg. PGF secretion rate did not change, the renal
venous concentrations merely changing due to the dilution effects of
the blood flow changes.
Our findings confirm the work of Beckman and Zehr (1975], who showed
that a 50% reduction in renal blood flow in the dog, resulted in a
38% fall in PGE secretion rate. This is comparable to the fall of
about 35%, which we obtained.
Like Beckman and Zehr, and as in our rat experiments (Section II],
we assumed that the product of RPF and renal venous plasma prostaglandin
concentration does give an index of secretion rate. We cannot rule out
the possibility that intrarenal degradation of prostaglandins is flow
dependent, such that at low flow rates, metabolism is more efficient
due to the low velocity of blood in the vessels. This would have the
effect of reducing the apparent secretion rate.
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Absolute renal blood flow is undoubtedly dependent on prostaglandin
production, since for any given pressure, we obtained a 50% reduction
in flow after inhibition of synthesis. PGE^ would appear to be the
main prostaglandin determining renal blood flow (Lonigro, Itskovitz,
Crowshaw and McGiff, 1973a). Infusion of prostaglandins of the E and
A series CO.01 - 0.3 ug kg min ) (Fulgraff, Brandenbusch and Heintze,
1974; and Tannenbaum, Splawinski, Oates and Nies, 1975) and arachidonic
-1 -1
acid (1.0 - 30.0 ug kg min , Tannenbaum et al, 1975) into the renal
artery of the dog, elevate renal blood flow and synthetase inhibition
prevents the effect of arachidonate only (Tannenbaum et al, 1975).
Renal prostaglandins may also determine the distribution of renal
blood flow. Indomethacin reduces inner cortical blood flow to a
greater extent than outer cortical flow (Itskovitz, Stemper, Pacholczyk
and McGiff, 1973). Arachidonic acid produces a rise in inner cortical
flow, without much effect on outer cortical flow, whilst PGE^ infusion
increased flow to all regions of the cortex in the dog (Chang,
Splawinski, Dates and Nies, 1975). In the rabbit arachidonic acid
infusion also selectively increases inner cortical flow (Larsson and
o II
Anggard, 1974).
It is, therefore, not surprising that the renal prostaglandins were
suspected in renal blood flow autoregulatiorl, especially since it has
been observed that as RAP falls over the autoregulation range, there
is a proportional fall in outer cortical blood flow, but inner'cortical
flow actually increases (McNay and Abe, 1970).
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In the conscious dog, indomethacin (2 mg/kg), (Zins, 1975], meclofenamate
(2 mg/kg) and the competitive synthetase inhibitor Ro 20-5720 (1 mg/kg)
(Kirschenbaum and Stein, 1976) failed to affect renal blood flow or
renal vascular resistance. However, no direct evidence of prostaglandin
inhibition was given in these reports.
In contrast, 4 mg/kg of meclofenamate was reported to reduce renal
blood flow in conscious dogs, although 10 mg/kg indomethacin did not
(Swain, Hendrickx, Boettcher and Vatner, 1975).
Intrarenal blood flow distribution is not affected by prostaglandin
synthetase inhibition in conscious dogs (Zins, 1975; and Kirschenbaum
and Stein, 1976) but in conscious rabbits a fall in inner cortical
flow is reported (Beilin and Bhattacharya, 1975).
Why should renal blood flow be resistant to the effects of synthetase
inhibition in the conscious dog, yet be dependent in the anaesthetised
state?
Taking precautions to prevent activation of the renin system, Satoh
and Zimmerman (1975a) failed to affect renal blood flow in the
anaesthetised dog with meclofenamate implying that the released
angiotensin causes an abnormal stimulation of the prostaglandin system.
It has been demonstrated that angiotensin causes the release of renal
prostaglandins from canine kidney (Aiken and Vane, 1973). Barbiturate
anaesthesia causes renin release and angiotensin production, which has
been shown to reduce renal blood flow (Burger, Hopkins, Tulloch and
Hollenburg, 1976). This would raise renal prostaglandin concentrations
by two mechanisms, namely by angiotensin induced release and by the
dilution effect of flow reduction.
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Additional factors may be present in the pump-perfused kidney. The
mere introduction of the superfusion bioassay system as used by
Herbaczynska-Cedro and Vane (1973) has been shown to elevate arterial
and renal venous PGE concentrations, possibly through kinin formation
(Satoh and Zimmerman, 1976a). Under such circumstances, the renal
blood flow becomes sensitive to prostaglandin synthetase inhibition.
It is possible that the tubing used in the pump circuit to perfuse
the kidney may produce a similar effect. The high resting resistance
to flow seen in the pump-perfused kidney will also raise renal venous
prostaglandin concentration through a dilution effect.
In seven conscious dogs we obtained resting renal venous PGE concentrations
of 191 - 25 pg/ml (n = 10), significantly lower than the levels
obtained in the acute studies at 100 and 150 mmHg, 361 ± 63 pg/ml
(n = 10, P < 0.05).
In conclusion, renal prostaglandins do not appear to mediate renal
blood flow autoregulation, but may play a role in determining absolute




In the canine kidney, by virtue of their vasodilator and natriuretic
actions, the renal prostaglandins may play a role in the control of
long term fluid and electrolyte balance and in protecting the kidney
against the detrimental effects of renal artery stenosis upon renal
function. Renal PGE is unlikely to mediate the antihypertensive role
of the kidney because of a return of the raised PGE, yet blood pressure
remained elevated. Moreover PGE can not circulate due to the pulmonary
degradation mechanism. Elevated PGA levels, which were seen in the few
dogs examined, may play a role in the control and distribution of extra¬
cellular fluid during the period of fluid retention.
In renal blood flow autoregulation in the dog, prostaglandins can not
be assigned a role other than in the control of absolute renal blood
flow. However, this is probably only an artefact of the anaesthesia
since in the conscious dog blood flow and intrarenal blood flow
distribution are unaffected by inhibition of prostaglandin synthetase,
which is further evidence for renal blood flow autoregulation being
mediated by a mechanism independent of prostaglandins.
Interpretation of the consequences of prostaglandin changes in the
kidneys of rats is complicated by the discovery that prostaglandins
are still natriuretic but potentiate vasoconstrictors and at
higher doses cause intrarenal vasoconstriction by themselves in this
species. The observed decrease in prostaglandin synthesis in the
clipped kidney probably results in attenuation of the vasoconstrictor
effects of angiotensin. The absence of a rise in PGE synthesis in
- 114 -
either Kidney strengthens the belief that the antihypertensive action
of the Kidney in this species is not due to PGE.
One problem in interpreting the consequences of changes in renal venous
prostaglandin concentrations in terms of effects on renal function, is
that there are at least three intrarenal sites of prostaglandin synthesis,
which may respond differently to the same stimulus. These sites are:-
al the sympathetic nerve endings, mainly in the cortex, where the
prostaglandins probably modulate sympathetic nerve activity
[Frame and Hedqvist, 19751.
bl the medullary renal interstitial cells (RIC si, which are rich
in precursors and can synthesise prostaglandins (Muirhead et al,
1973) and may play a role in sodium excretion.
cl the collecting duct cells, which according to Janszen and Nugteren
(19721 are even more active than RIC s at prostaglandin synthesis
and possibly account for the anti-vasopressin effects.
It is possible that this may explain why the actions of endogenous
prostaglandins cannot always be simulated by administration of exogenous
prostaglandins.
In evaluating changes in renal venous prostaglandin concentrations in
terms of intrarenal effects it must be realised that the concentrations
locally at the site of action, rather than renal output per se, is of
importance. In examining the renal prostaglandin releases in terms of
possible extrarenal roles, the actual rate of output is of importance as
is the stability in the circulation, particularly in the pulmonary circuit.
- 115 -
This study has confirmed recent work that the antihypertensive action
of the kidney in rat is not due to prostaglandins and that autoregulation
of renal blood flow in the dog kidney is also due to a mechanism other
than prostaglandins.
The roles of prostaglandins in the hypertensive dog was only speculated
and it is in this system that further investigations would be of
interest.
Tables A-M
In the following tables, in addition to those abbreviations on
page iii, there are the following:-
SBP systolic blood pressure in mmHg
DBP diastolic blood pressure in mmHg
mBP mean blood pressure in mmHg
BV blood volume in ml/kg
PV/IFV ratio of plasma to interstitial fluid volume
Na + plasma sodium concentration in mEq/1
K+ plasma potassium concentration in mEq/1




bs below sensitivity of detection
Fluid volumes are expressed in ml/kg and Prostaglandins in pg/ml.




SBP DBP mBP HR CVP
c 107 84 116 57 CMCO
c 143 82 107 111 2.6
2 191 122 147 87 3.2
4 195 124 151 75 3.8
7 200 128 156 78 4.2




PV BV Ht ECFV IFV PV/IFV Na
+
K BW
C 61.6 104 41 285 223 0.275 160 4.5 16.5
C 68.2 109 38 360 292 0.234 151 4.12 16.5
2 72.0 112 36 425 353 0.204 162 4.20 16.5
4 64.0 102 37 331 267 0. 240 150 4.24 16.4
7 65.8 106 38 194 228 0.288 133 3.88 16.4








rv a rv a rv a rv a
c 130 180 200 200 600 540 420 630
2 230 190 445 240 570 bs 665 510
5 303 310 510 230 330 bs 690 890
7 210 160 120 190 bs bs 1035 730
10 130 835 120 340 490 940 455 1820
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Table B: 'Melody'
SBP DBP mBP HR CVP
c 171 114 125 94 3.1
c 155 90 107 94 1.9
1 168 114 136 125 3.8
2 211 132 154 99 1.5
4 211 139 150 110 2.3
7 207 129 139 110 5.0




PV BV Ht ECFV IFV PV/IFV Na + +K BW
C 65.0 107 39 342 277 0. 236 150 3.25 19.0
c 58.7 96 39 390 332 0.177 141 3.00 19.0
2 61 .4 102 40 359 301 0.204 144 3.42 18.5
4 64.3 105 39 357 292 0.220 144 3.43 18.5
7 66.7 109 39 322 256 0.261 117 3.00 18.0
11 60.0 98 39 400 341 0.175 144 3.91 18.5
PGE2 PGF2 c*
RV A RV A
C 129 1040 175 515
c 1370 - 2950 -
2 372 220 240 bs
5 973 180 . 440 420
7 415 1490 188 450






PV BV Ht ECFV IFV PV/IFV Na + +K BW
c 70.2 111 37 312 242 0. 290 144 3.80 24.6
2 76.0 119 36 308 232 0. 326 157 4.24 25.0
4 78.0 132 41 347 269 0.290 151 4.20 25.0
7 66.3 116 43 316 250 0.265 150 4.12 25.0







c 210 174 251 181
2 490 818 260 950
5 735 880 480 240
7 510 800 525 508
10 610 620 325 190
14 412 830 215 270
21 380 - 200 -
SBP DBP mBP HR CVP
C 186 114 144 89 4.1
c 180 120 146 93 -
1 191 134 154 93 -
2 183 123 157 72 8.2
4 191 129 151 72 5.2
7 191 134 153 89 -
11 191 134 156 82 5.3
18 197 134 159 96 3.7
- 119 -
Table D: 'Sadie'
SBP DBP mBP HR CVP
c 178 109 120 86 3.9
3 204 136 164 78 8.3
5 169 108 135 68 13.9
7 170 108 132 63 9.1
10 168 104 132 73 -
14 178 113 144 83 -
17 162 109 135 73 6.9
19 176 115 138 73 ■-
*1 171 112 141 94 3.1




* Days after unclamping
PV BV Ht ECFV IFV PV/IFV Na + +K BW
c 58.2 87 33 313 255 0.228 142 4.25 19.0
4 81 .2 117 31 355 273 0.297 142 4.07 19.0
7 77.7 112 31 418 340 0.228 150 3.82 19.0
11 79.7 114 30 322 243 0.251 143 4.11 18.0
18 75.5 108 29 369 293 0.258 146 3.75 17.5










c 228 2140 107 475 1415 1860 2730 2510
1 535 487 279 352 1560 1960 2345 4000
3 504 540 242 117 2820 2440 4420 4275
5 292 282 260 264 1390 1540 2400 3345
7 256 327 160 295 2790 2405 2330 4000
12 233 196 203 124 1770 1465 4510 2730
23 486 173 bs 172 2300 1820 3455 high
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Table E: 'Flora'
SBP DBP mBP HR CVP
c 175 104 129 115 3.9
c 182 104 129 99 2.1
c 168 93 125 89 2.1
1 193 125 161 120 4.6
2 211 132 168 81 4.6
3 218 143 164 110 4.6
4 236 150 175 110 3.9
7 179 114 136 125 4.6
9 188 127 146 89 -
11 167 111 133 94 -
14 178 119 152 130 -




pv bv Ht ecfv ifv pv/ifv Na
+
K bw
C 68.2 108 37 312 244 0.278 121 2.80 23.0
C 63.4 101 37 302 239 0.265 128 3.49 23.0
2 57.8 95 39 299 241 0.240 142 3.73 22.8
4 51 .7 83 38 297 24 5 0.211 147 3.84 22. 6
7 61.6 99 38 293 231 0.266 152 3.82 21. 5










C 110 193 190 170 1500 2950 565 565
2 114 82 140 132 1790 1705 420 520
5 114 122 84 140 10400 8520 2705 2410
7 90 102 112 112 4940 6750 1825 2320
10 94 - 112 - 3480 - 1770 -
14 100 136 bs 126 9320 11130 1410 3425
17 56 158 bs 130 2055 3235 1335 1205
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Table F: 'Apricot'
SBP DBP mBP HR CVP
c 150 93 121 73 1.8
c 150 96 118 89 1.5
1 164 93 118 92 2.6
2 167 104 137 73 7.4
4 170 115 141 - 5.9
11 174 •115 141 63 6.7




PV BV Ht ECFV IFV PV/IFV Na +
+
K BW
C - __ 44 286 - - 163 3.65 18.7
C 67.4 118 43 357 289 0.233 150 3.43 17.4
2 74.3 128 42 314 240 0.309 148 3. 51 18.1
11 53.5 104 39 294 231 0. 275 174 4.62 19.2
23 82.1 116 29 400 318 0.258 148 3.88 18.8
pge2 pgf Z. C* pga2 pgb2
RV a RV a RV a RV a
c 127 260 90 263 680 820 145 395
c 130 87 190 130 820 870 260 215
2 113 220 105 250 1050 1955 710 500
5 130 135 123 145 955 1045 280 375
10 150 100 115 187 690 730 255 170
14 123 87 160 123 800 800 135 165






PV BV Ht ECFV IFV PV/IFV Na
+
K BW
c 75.8 135 44 276 200 0.378 142 3.5 20.4
c 68.3 117 44 323 258 0.253 143 3.4 20.4
2 78.4 107 27 367 288 0.272 144 4.0 20. 0
4 77.5 105 26 401 323 0.240 117 3.0 20.6
7 - - 30 295 - - 147 4.0 20.6
11 85.7 125 31 314 228 0.375 139 4.4 20.6







C 210 190 100 85
C 155 1709 120 370
2 400 265 122 bs
5 155 96 119 119
7 110 120 170 115
10 180 310 180 320
14 135 135 bs 105
SBP DBP mBP HR CVP
C 152 104 130 104 1.9
C 170 100 126 94 4.8
1 152 100 130 104 -
2 179 107 132 99 4.1
4 178 111 133 78 4.8
7 174 115 133 83 2.3
11 178 119 137 63 3.7
14 - - 125 - -




Clamped kidney 35.04 gm
Untouched kidney 57.40 gm
PV BV Ht ECFV IFV PV/IFV Na +
+
K BW
c 63.4 102 38 337 234 0.270 158 4.15 17.9
c 63.5 102 38 400 297 0.213 152 3.91 17.9
c 63.4 102 38 - - - - - 17.6
2 69.2 108 36 365 257 0.269 154 3.55 17.4
4 63. 6 103 38 348 227 0.332 145 3.67 17.3
11 63.4 102 38 338 272 0.234 185 5.17 16.7
pge2 pgf2c<
rv a rv a
c 156 183 bs 76
C 214 214 106 80
2 352 178 360 86
5 311 289 280 176
8 3950 1700 340 480
10 285 2200 296 636
SBP DBP mBP HR
1
CVP
C 155 90 119 98 3.8
C 132 77 100 84 4.3
1 132 90 113 76 2.4
2 - - 126 56 6.7
4 148 94 119 71 2.9
11 142 94 103 76 1.0
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Table I: 'Whisper'
Clamped Kidney 44.0 gm
Untouched Kidney 50.4 gm
* Days post-indomethacin (days 22 and 23 post clamp respectively].
PV BV Ht ECFV IFV PV/IFV Na
+
K BW
c 69.9 113 38 296 226 0.310 150 4.33 18.2
c 64.3 107 40 356 291 0.221 160 4.23 17.5
2 66.9 111 40 344 278 0.241 157 3.43 18.0
4 69.9 95 38 386 318 0.221 148 3.69 18.1
11 69.9 113 38 304 234 0.300 166 3.83 18.3
SBP □BP mBP HR CVP
C 152 100 119 76 3.8
C 148 100 119 76 5.2
1 171 113 139 71 r\CD
2 168 110 126 62 -
4 158 100 126 62 6.7
7 161 103 129 71 5.2
11 174 116 139 62 5.2
14 190 132 161 67 -
16 155 110 129 64 1.4
*4 155 110 129 64 0.23
*5 146 106 127 116 0.26
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Table J: 'Topaz'
SBP DBP mBP HR CVP
c 167 79 112 93 5.00
c 171 79 100 72 3.48
1 171 88 110 83 2.27
2 163 90 108 74 1.96
4 167 92 112 86 1. 59
7 175 94 114 84 3.18
10 184 88 108 64 2. 50
PV BV HT ECFV IFV PV/IFV Na
+
K BW
C 71. 8 116 38 336 264 0.272 138 2. 62 23.7
C 71. 5 115 38 335 264 0.271 152 3.80 24.1
2 68.8 113 39 342 273 0.252 155 3.60 24.1
4 75.2 121 38 357 236 0.319 157 3.83 24.3
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Table K: 'Joyless'
SBP DBP mBP HR CVP
c 136 88 112 83 4.0
c 162 96 119 90 3.5
1 154 92 108 89 1.5
2 142 85 108 84 2.7
4 131 73 100 83 1.2
7 154 92 123 89 2.7




* Days post-indomethacin (100 mg/day).
PV BV Ht ECFV IFV PV/IFV Na
+
K BW
C 63.2 107 41 333 269 0.235 150 4.3 23.4
C 68. 9 123 39 357 288 0.289 180 5.21 23.4
2 75.9 120 37 335 259 0.293 155 3. 56 23.0
pge2 pgf2„
RV a CV RV a CV
C 245 330 - 180 198 -
C 350 270 - 165 200 -
Pre- Indomethacin 515 - - 216
Post -Indomethacin 210 - - 160
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Table L: 'Jigsaw'
Kidney Weights: Clamped 59.52 gm
Untouched 65.57 gm
PV BV Ht ECFV IFV PV/IFV Na + +K BW
c 66.3 111 40 351 285 0.233 155 CD"sTCQ 18.9
c 63.6 108 41 352 288 0.221 162 3.84 18.9
c 66.2 110 40 354 288 0.230 161 4.18 18.9
PGE2 PGF2^
RV A RV A
C 380 160 236 240
C 650 3675 276 242
C 315 - 260 -
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Table M: PGE and PGF Renal Venous Plasma Concentrations
and Secretion Rates at Different Renal Artery
Perfusion Pressures
RAP
(mmHg) PGE Concentration (pg/ml)
50 290 1630 460 370 350 150
100 390 316 480 250 280 150
150 200 730 680 240 140 -
200 180 880 420 240 220 220
PGE Secretion Rate (ng/min)
50 2.91 34.23 8.74 9.99 10.40 1.5
100 7.16 6.95 23.04 12.75 12.32 2.4
150 3.40 28.49 44.88 14.40 6.16 -
200 4.25 32.56 23.10 20.64 11.00 4.4
PGF Concentration (pg/ml)
50 - 1790 380 809 220 -
100 - 102 290 306 150 -
150 - 400 612 340 100 -
200 - 880 240 220 130 -
PGF Secretion Rate (ng/min)
50 - 37. 59 7.22 18.72 6.60 -
100 - 2.24 18.72 15.61 6. 60 -
150 - 15.60 40.39 40.39 4.40 -
200 - 32.56 13.20 13.20 6.80 -
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RENAL FUNCTION AND
RENAL VENOUS PROSTAGLANDIN
CONCENTRATIONS DURING DIFFERENT STAGES OF
EXPERIMENTAL RENAL HYPERTENSION IN THE RAT
G.W. SMITH & LILIANA I. SOMOVA1
Department of Pharmacology, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ
1 Renal hypertension was produced in rats and the changes in renal function, renal venous pro¬
staglandin E2 and F2n concentrations and secretion rates were studied at various times.
2 Renal plasma flow transiently fell in the ischaemic kidney 2 weeks after clamping, whilst that of the
other kidney did not change. Glomerular filtration rate remained constant in both kidneys throughout
the entire study.
3 Prostaglandins E2 and F2(l concentrations rose in the venous plasma from the ischaemic kidney,
but did not change in the other kidney and appeared to be inversely related to renal plasma flow.
4 Calculated secretion rate of both prostaglandins fell in the ischaemic kidney and did not change in
the other kidney.
5 Clamping the second kidney, two weeks after the first, caused a further elevation in blood pressure,
a fall in renal plasma flow and a fall in prostaglandin secretion rate in both kidneys.
6 The implications of these prostaglandin changes are discussed.
Introduction
Acute renal ischaemia increases the concentration of
prostaglandin E-like material in renal venous blood of
the dog and this has been interpreted as a rise in
output of renal prostaglandins (McGifT, Crowshaw,
Terragno, Lonigro, Strand, Williamson, Lee & Ng,
1970). Such a mechanism may protect the kidney
from the antinatriuretic/vasoconstrictor influence of
the renin and sympathetic systems (Lonigro,
Terragno, Malik & McGiff, 1973).
The contralateral renal prostaglandins have also
been assigned a role. The contralateral kidney of the
Goldblatt hypertensive dog has an antihypertensive
function, independent of excretion (Grollman,
Muirhead & Vanatta, 1949). Such a system is also
present in the rat kidney, when perfused at
hypertensive pressures (Tobian, Schonning & Seefeldt,
1964). Lee (1973) believes that the renal pro¬
staglandins may play a role.
No study has yet examined renal venous pro¬
staglandin concentrations in chronic renal ischaemia
of experimental origin nor attempted to evaluate the
rate of output of renal prostaglandins.
1 Present address: Research Group of Hypertension,
Medical Academy, Sofia 31, Bulgaria.
In this study we examined renal function and renal
venous prostaglandin E2 and F2n concentrations of
both kidneys of rats at various stages after clamping
the left renal artery and also after clamping both renal
arteries.
Methods
One hundred and thirty six male and female Wistar
rats, of approximately similar size and fed on a
standard laboratory diet, with water ad lib., were
divided into seven experimental groups, 30 rats
serving as controls. Renal hypertension was induced
by clipping the left renal artery with a small silver clip
(first operation) and in some rats, clipping the right
renal artery (second operation) two weeks later. The
rats were killed at various stages after clipping as
follows: group 1, 20 rats killed 1 week after the first
operation; group 2, 20 rats killed 2 weeks after the first
operation; group 3, 20 rats killed 3 weeks after the first
operation; group 4, 20 rats killed 4 weeks after the first
operation; group 5, 20 rats killed 1 week after the
second operation; group 6, 20 rats killed 2 weeks after
the second operation and group 7, 16 rats killed 10
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weeks after the second operation (the chronic
hypertensive group).
The rats were weighed weekly and arterial blood
pressure was measured by the indirect tail-cuffmethod
using a Rat Blood Pressure Monitor (Huntingdon
Instruments, England).
From each group, 6 to 8 rats were used for the
estimation of bilateral renal function, namely renal
plasma flow (RPF) and glomerular filtration rate
(GFR) and the remaining rats were used for the
estimation of renal venous prostaglandin con¬
centrations.
RPF and GFR were estimated by means of the
clearances of para-aminohippurate (PAH) and of
inulin respectively. The rats were anaesthetized with
pentobarbitone (40 mg/kg i.p.) and tracheotomized.
The left subclavian vein was catheterized for the
infusion of the clearance solution at a rate of
0.05 ml/min by means of a motor driven syringe
(Braun). The clearance solution was composed of 1%
inulin, 1% PAH and 2% Na2S04 dissolved in 0.9%
w/v NaCl solution and buffered to pH 7.4 with
bicarbonate.
Both ureters were catheterized after the method of
Mercer (1971) and a lOmin urine sample was
collected from each ureter 50 min after the infusion
had begun. After heparinization (1000 u/kg), blood
samples (0.5 ml) were removed from a carotid artery
catheter 50 and 60 min after the start of the infusion,
for the calculation of mean plasma PAH and inulin
concentrations, which we tried to hold at about 7 and
30 mg% respectively.
The blood was centrifuged in Eppendorf tubes and
0.2 ml of plasma removed and subjected to plasma
protein precipitation with Somogyi reagent. The urine
was carefully transferred to a volumetric flask and
diluted to 100 ml. Diluted urine and protein-free
plasma were analysed for inulin and PAH using a
resorcinol method for the former and N (1-napthyl)-
ethylene diamine as a coupling reagent for the latter
and both were compared with standard solutions in a
spectrophotometer (Bausch and Lomb, SP 20,
U.S.A.).
The clearances of PAH and inulin were calculated
and expressed in terms of body weight. The extraction
ratio for PAH was not taken into account. Girndt &
Ochwadt (1969) have shown that 4 weeks after
clamping a renal artery, PAH extraction was
unaltered in both the clamped and the contralateral
kidneys (0.84 approx.).
Blood samples for the estimation of prostaglandins
were drawn from the renal veins of anaesthetized rats
after a midline laparotomy and catheterization of the
inferior vena cava. Within each group, the left and
right renal venous blood samples were pooled
separately (final volume about 10 ml). A known
amount of deuterium isotope, 1 pg d4 prostaglandin E2
and 500 ng d4 prostaglandin F2a was added to each
plasma sample and the prostaglandins were extracted
and subjected to silicic acid column chromatography
(Poyser, 1972). Methyl ester/methoxime/trimethylsilyl
and methyl ester/trimethylsilyl derivatives were made
of the extracted prostaglandins E2 and F2a
respectively (Thompson, Los & Horton, 1970;
Blatchley, Donovan, Horton & Poyser, 1972). Using
multiple ion detection (Finnigan 3000D mass
Table 1 Changes in blood pressure (mmHg) and prostaglandin (PG) level (ng/ml) in renal venous blood of
control and renal hypertensive rats
Blood pressure PGE2 PGF2a
Group (n) Systolic Diastolic Left renal Right renal Left renal Right re,
vein vein vein vein
Controls (30) 126 + 2.73 100 + 2.55 4.0 3.8 2.7 2.2
1 (20) 139 + 5.17 1 1 1 ±4.69 4.4 2.7 3.7 2.1
P<0.05 P<0.05
2 (20) 142 ±4.71 1 12 + 3.91 5.6 3.6 4.3 2.7
PC0.01 P <0.02
3 (20) 148 + 5.13 123 + 4.26 4.6 2.6 3.2 2.0
P<0.001 P<0.001
4 (20) 148 + 5.62 1 18 + 4.14 3.2 5.0 1.2 2.9
P<0.001 P<0.001
5 (20) 1 52 ± 4.57 121 ±3.87 3.0 4.5 1.6 4.4
P<0.001 P<0.001
6 (20) 1 93 ± 7.61 153 + 7.84 4.7 6.2 2.7 3.1
PC0.001 P< 0.001
7 (16) 183 + 5.55 150 + 5.14 2.9 4.5 1.9 3.3
P< 0.001 P<0.001
n is the number of rats in each group. Values are mean ± s.e. Groups 1 to 4 had clipped left kidneys. Groups 5 to 7
had both kidneys clipped.
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spectrometer), the ratio of proton to deuterium peaks
of the prostaglandin derivatives was obtained and
compared with a standard calibration curve over the
range of 1 to 1000 ng of protium. (Hensby & Naylor,
1974.)
Statistical analysis of the results was performed by
Student's two-tailed t test, except for the renal function
results, where a one-tailed t test was used (Dixon &
Massay, 1969). Values are expressed as mean + s.e.




One week after the production of renal ischaemia
(groups 1 to 4), there was a significant rise in blood
pressure, which reached a peak by the third week
(group 3). Systolic blood pressure rose from
126 ± 2.73 mmHg to 148±5.13mmHg (/>< 0.001)
and diastolic pressure increased from
100± 2.55 mmHg to 123 ±4.26 mmHg (P<0.001)
three weeks after clamping (group 3) (Table 1).
Cardiac hypertrophy also occurred over this period
as seen by the rise in the heart/body weight ratio
(Table 2). The left kidney/body weight ratio rose in
group 1 rats but fell in group 2 and was not
significantly different from control in later groups. The
right kidney hypertrophied in each of the unilaterally
clamped groups, except for group 2 (Table 2).
An inverse relationship between renal mass and the
level of systemic hypertension was noted in almost all
cases.
During ischaemia of the right kidney, as well as of
the left, (groups 5, 6 and 7), systolic and diastolic
pressures rose further, within the range 126/100 to
183/150 mmHg 10 weeks after the second operation
(the chronic hypertensive group).
The left, earlier ischaemic kidney, was now firm and
shrunken, especially in the chronic group (group 7).
The right kidney, which had previously been
hypertrophied before the second operation, was now
not significantly different from control. Cardiac
hypertrophy was very marked in these bilaterally
ischaemic rats.
Renal function changes
After unilateral renal ischaemia, RPF of the clamped
kidney fell significantly 2 weeks after clamping
(group 2), from 8.23 ± 1.28 ml min"1 kg-1 to
4.28 ± 1.55 ml min-1 kg-1 (P<0.05) and subsequently
rose again to control values (Table 3). The con¬
tralateral kidney showed no significant change in RPF
at this time. Due to the well maintained GFR, the
filtration fraction (FF) rose significantly only in the
ischaemic kidneys of group 2 rats.
On clamping the right kidney, RPF fell 2 weeks
later in group 6 from 9.12 ± 1.31 ml min"1 kg-1 to
3.43 ± 0.25 ml min"1 kg"1 (P< 0.025) (Table 3). Left
RPF also fell, from 8.23 ± 1.29 ml min"1 kg"1 to
4.44 + 0.44 ml min-1 kg-1 (P<0.025). This fall was
also significant (P< 0.0005) when compared with
group 4, which had undergone exactly the same
procedures and time course, except for the second
Table 2 Average organ/bodyweights in control and experimental rats.
Group (n) Body weight Heart/body Left kidney/ Right kidney/
(g) weight body weight body weight
Controls (30) 257 + 12 32.4 + 0.6 35.2+0.5 35.9 + 0.6
1 (20) 226 + 8 36.7 + 1.2 39.8 ± 1.8 42.7 + 2.0
P<0.01 P<0.02 PC0.001
2 (20) 228 ± 1 5 35.4 + 0.7 32.6 ± 1.2 35.5± 1.4
P<0.01 P<0.05 P> 0.5
3 (20) 248 ±8 34.2 + 0.5 35.3+ 1.8 40.4+1.2
P<0.05 P> 0.5 P<0.01
4 (20) 212 ± 11 38.5+1.2 34.8 ± 1.3 41.3 + 1.3
P< 0.001 P> 0.5 P<0.001
5 (20) 292± 15 33.4+1.4 31.3 ± 1.1 35.5+1.2
P> 0.5 PC0.01 P> 0.5
6 (20) 188+13 41.5+1.4 31.6± 1.9 40.1 +2.3
P<0.001 PC0.05 P> 0.05
7 (16) 187±16 41.4 + 2.1 30.2 + 2.1 39.8 ±2.7
P<0.001 P <0.02 P>0.1
Body weights are expressed in grams. Organ/body weights are expressed x 1 0~4. n is the number of rats in
each group. Values are mean±s.e. Groups 1 to 4 had clipped left kidneys. Groups 5 to 7 had both kidneys
clipped.
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operation. As GFR was so well maintained, FF rose
in the left kidneys of group 6. In group 7, the chronic
hypertensive group, no difference was detected
between either kidney and control.
Prostaglandins E2 and F2a renal venous con¬
centrations
After the first operation, left renal venous pro¬
staglandin E2 and F2n concentrations were higher
than control, whereas the concentrations in the right
renal venous plasma were similar or slightly lower
than control, except for group 4 (see Table 1, groups 1
to 4).
After the second operation, prostaglandins E2 and
F2(i concentrations rose in the right renal venous
plasma 1 week later (group 5). By the second week
(group 6), prostaglandin E2 had risen even more in the
right renal venous plasma but prostaglandin F2n had
fallen, although still above control. Both pro¬
staglandins rose transiently in the left renal venous
plasma. In the chronic hypertensive rats (group 7),
right renal venous prostaglandin E2 and F2a con¬
centrations were higher than control, in contrast to the
left renal venous concentrations, which were lower
than control.
Prostaglandin secretion rates
Secretion rate of each prostaglandin may be
calculated from the product of the total mean RPF
and the prostaglandin concentration for each group
since prostaglandins appear to be released on
synthesis (Anggard, Bohman, Griffin, Larsson &
Maunsbach, 1972). This assumes that all the arterial
prostaglandins presented to the kidney are cleared in
one passage because of the high activity of the
metabolizing enzyme, 15 hydroxy prostaglandin
dehydrogenase, in the rehal cortex (Anggard, Larsson
& Samuelsson, 1971). The clamped kidney showed
a fall in secretion rate of prostaglandin E2 from
8.68 ng/min to 6.24, 5.57, 8.51 and 4.84ng/min in
groups 1, 2, 3 and 4 respectively. Prostaglandin F2a
secretion rate also fell, from 5.86 ng/min to 5.25, 4.28,
5.92 and 1.81 ng/min in each of the above respective
groups (see Table 4). The contralateral kidney of these
groups showed no change in secretion rate of either
prostaglandin. After ischaemia of the right kidney,
secretion rate of both prostaglandins began to fall in
the right kidney and continued falling in the left kidney
(groups 5, and 6). A subnormal secretion rate of both
prostaglandins existed in the two kidneys of the
chronic hypertensive group (group 7).
Discussion
Four weeks after clamping a renal artery, the resultant
hypertension was associated with normal PAH and
inulin clearances in both the clamped and con¬
tralateral kidneys of rats (Girndt & Ochwadt, 1969).
However, medullary blood flow was elevated in the
contralateral kidney as determined by the 86Rubidium
method. Our results are essentially in agreement with
these findings. However, at variance with this, Kramer
& Ochwadt (1974) reported that rat kidneys clamped
6 to 10 weeks previously, had lower PAH and inulin
clearances in comparison with the contralateral
kidney.
Table 3 Glomerular filtration rate and renal plasma flow
Glomerular filtration rate Renal plasma flow Filtration fraction
Group (n) Left kidney Right kidney Left kidney Right kidney Left kidney Right kidney
Controls (10) 1.80±0.25 2.20 ± 0.28 8.23± 1.29 9.12 ± 1.31 0.24 ±0.03 0.27 ±0.05
1 (8) 1.50 ±0.26 2.66+0.28 6.34 + 1.32 10.14± 1.25 0.28 ±0.03 0.30 ±0.04
P> 0.2 P>0.05 A >0.05 P> 0.2 P> 0.2 P> 0.2
2 (8) 1.57 ±0.39 2.41 +0.59 4.28± 1.55 8.56 ±2.92 0.41 ±0.07 0.38 ±0.05
P> 0.2 P> 0.2 P<0.05 P> 0.2 P>0.05 P>0.1
3 (8) — — 7.46± 1.12 9.00 ± 1.39 — —
P> 0.2 P> 0.2
4 (8) 1.88+0.18 2.09 + 0.33 7.59 + 0.35 1 0.95 ± 2.25 0.21 +0.02 0.28 + 0.06
P> 0.02 P> 0.2 P> 0.2 P> 0.2 P> 0.5 P> 0.5
5 (8) 1.62+0.1 5 2.09+0.23 5.85 ±0.95 7.14 ± 0.89 0.30 + 0.02 0.31 ±0.01
P> 0.2 P> 0.2 P> 0.05 P>0.05 P> 0.05 P> 0.2
6 (7) 1.84 ±0.27 1.45+0.35 4.44 ±0.44 3.43 ±0.25 0.42 ±0.09 0.45 ± 0.1 4
P> 0.2 P> 0.05 P< 0.025 P<0.025 P> 0.05 P> 0.2
7 (6) 1.50 + 0.16 1.68 ±0.19 5.49 ±0.79 6.30 ±0.75 0.34 + 0.06 0.37 ±0.08
P> 0.2 P>0.05 P>0.05 P> 0.05 P>0.1 P>0.1
Values are mean ± s.e. Clearances are expressed in ml min~1 kg-1 body weight, n is the number of rats in each
group. Groups 1 to 4 had clipped left kidneys. Groups 5 to 7 had both kidneys clipped.
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suggested that increased secretion of prostaglandin E
mediated autoregulation of blood flow since
indomethacin abolished autoregulation and the pro¬
staglandin release. However, this concept may be no
longer tenable in the intact, naturally perfused kidney
(Owen, Ehrhart, Weidner, Haddy & Scott, 1974;
Venuto, O'Dorisio, Ferris & Stein, 1975; Anderson,
Taher, Cronin, McDonald & Schrier, 1975). Using
essentially the same approach as Herbaczynska-
Cedro & Vane, autoregulation was found to be
resistant to meclofenamate (10 mg/kg, i.v.) although
absolute flow fell (Dighe, Hall, Smith & Ungar,
unpublished results). It remains to be seen whether rat
kidney behaves in a similar manner.
Renal prostaglandins may have a natriuretic role
and protect the kidney against the vaso-
constrictor/antidiuretic influence of the renin and
sympathetic systems (McGiff & Nasjletti, 1973;
Lonigro, et al., 1973). However, in the isolated kidney
of the rat, unlike other species, prostaglandin E2
potentiates renal sympathetic nerve stimulation and at
higher doses causes vasoconstriction similar to that
induced by prostaglandin F2a (Malik & McGiff,
1975).
We have shown that prostaglandin E2 and F2a con¬
centrations rise in the plasma from ischaemic kidneys,
whereas the contralateral renal venous concentrations
remain unaltered or may perhaps fall slightly. As
Figure 1 shows, there is an inverse relationship
between prostaglandin E2 concentration and RPF for
both kidneys. This may either be a result or a cause of
the blood flow changes. Thus an increase in pro¬
staglandin E2 or F2a concentrations may reduce RPF
by the mechanism described by Malik & McGifT
(1975) and conversely a fall in RPF may be due to a
fall in prostaglandin concentration.
Alternatively, the concentration changes may be a
consequence of flow changes. This is supported by the
findings of Beckman & Zehr (1975) in the dog. On
halving renal blood flow, renal venous prostaglandin
Table 4 Estimated prostaglandin (PG) secretion rates (ng/min) in kidneys from control and experimental rats
pge2 pgf2u
Group Left kidney Right kidney Left kidney Right kidney
Control 8.68 8.71 5.86 5.04
1 6.24 6.82 5.25 5.31
2 5.57* 8.06 4.28* 6.05
3 8.51 6.65 5.93 5.1 1
4 4.84 11.41 1.81 6.62
5 5.62 9.25 2.64 9.04
6 4.13* 5.51* 2.37* 2.75*
7 3.08 6.67 2.02 4.81
Values were obtained from the product of total mean RPF of each group and the respective prostaglandin con¬
centration and are expressed in nanograms per minute. Groups 1 to 4 had left kidneys clipped. Groups 5 to 7
had both kidneys clipped.
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Figure 1 Systolic and diastolic blood pressures
(mmHg), renal venous prostaglandin E2 con¬
centrations of the left (•) and right (■) kidneys and
RPF (white bars) and GFR (black bars) of the left and
right kidneys respectively in each pair, at different
stages of hypertension. Values are mean + s.e.
McGiff et al. (1970) propose that the kidney
releases prostaglandin-like material in response to
reduced renal blood flow caused by constricting the
renal artery. Herbaczynska-Cedro & Vane (1973)
obtained a rise in renal venous prostaglandin E-like
material on reducing perfusion pressure and renal
blood flow, in the pump perfused canine kidney and
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E2, as detected by radioimmunoassay, rose, but
calculated secretion rate fell. We have also obtained
similar results in the pump perfused canine kidney
(Dighe, Hall, Smith and Ungar, unpublished
observations). This is in contrast to what is generally
believed and demonstrates the possible fallacy of
equating concentration changes with secretion
changes especially when concentration and flow
change in an inverse manner as they do in the clamped
kidney.
Our results also suggest that secretion rates of pro¬
staglandin E2 and F2n fall in the chronically ischaemic
rat kidney, with little change in the contralateral
kidney. It must be borne in mind that our secretion
figures were obtained from two groups of rats, namely
those used for prostaglandin estimations and those for
renal function tests, but there is no reason why these
rats should not have been representative.
A reduced release of prostaglandin E-like material
by the isolated kidney of one kidney Goldblatt rats,
perfused at constant flow and challenged with pressor
doses of noradrenaline, has been reported (Leary,
Ledingham & Vane, 1974). Reduced synthetic
capacity of prostaglandins was also found in the
kidneys of renal and spontaneously hypertensive rats
(Sirvios & Gagnon, 1974).
In contrast, using radioimmunoassay, Jaffe. Parker,
Marshall & Needleman (1972) observed a rise in pro¬
staglandin E in both the clamped and contralateral
kidneys of chronic hypertensive rats. Arterial levels
were also raised, suggesting a genuine increase in
synthesis, but not necessarily from the kidney.
In earlier investigations (Somova, 1971; 1973) an
increase in prostaglandin E-like material was seen in
the ischaemic kidney of the rat during the acute phase
of hypertension, with a decrease in the chronic stages.
The contralateral kidney has an endocrine
antihypertensive role, distinct from excretion as
demonstrated by Grollman et al. (1949) and Kolff
(1958) in the dog. Similar findings have been reported
in the rat kidney, when introduced into the circulation
of the hypertensive rat (Tobian et al., 1964).
Muirhead, Germain, Brooks & Stephenson (1973)
have attributed this property to the renal medulla and
probably to the renal interstitial cells, which have been
shown to synthesize prostaglandins. Rabbit reno-
medullary lipid is antihypertensive in rat (Muirhead,
Leach, Daniels & Hinman, 1968) and rat renal
medulla, especially that from hypertensive rats, is anti¬
hypertensive when implanted into hypertensive rats
(Tobian & Azar, 1971). However, the antihyper¬
tensive principle may not be the renal prostaglandins
but the neutral lipid (ANRL), which the renal
interstitial cells also elaborate (Muirhead, Leach,
Germain, Byers & Armstrong, 1974).
Certainly our results do not agree with the concept
that the antihypertensive function of the kidney is due
to an enhanced release of prostaglandin E2 since
secretion rate in the contralateral kidney does not
change.
The authors are indebted to Dr C.N. Hensby for performing
the prostaglandin estimations. L.I.S. was generously
supported by a British Council Grant. G.W.S. holds an
M.R.C. scholarship.
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renal blood flow auto regulation
and renal venous prostaglandins
in the pump-perfused canine kidney {In situ)
K.K. DIGHE, JANET C. HALL, G.W. SMITH & A. UNGAR
Department of Pharmacology, University of Edinburgh,
1 George Square, Edinburgh EH8 9JZ
1 Renal autoregulation of blood flow was re-examined in the pump-perfused canine kidney and con¬
centrations of prostaglandins E and F in the renal venous plasma were measured by
radioimmunoassay.
2 At low perfusion pressures, below the range of autoregulation, prostaglandin E and F con¬
centrations rose and calculated prostaglandin E secretion rate fell.
3 Meclofenamate (lOmg/kg, i.v.) reduced renal blood flow and prostaglandin E and F secretion
rates, but did not abolish autoregulation.
4 Renal prostaglandins do not appear to mediate autoreguiation in the kidney but may affect the
level at which flow is controlled.
Methods
Ten mongrel dogs of either sex. weighing between 8
and 15.5 kg were used. They were anaesthetized with
pentobarbitone (30 mg/kg, i.v.) and surgical
diathermy was used in subsequent operative
procedures (there was no significant blood loss). Each
animal was tracheotomized and systemic blood
pressure was measured from the left femoral artery.
Temperature was held at 37°C by a heating pad
controlled by a thermistor rectal probe. A midline
laparotomy was performed and a catheter placed in
the left renal vein via a femoral vein, for renal venous
blood sampling. The left ovarian or spermatic vein
was ligated. Hypotonic saline (0.8% w/v NaCl
solution) was infused intravenously at about 2 ml/min
to ensure adequate urine flow. The animal was injected
with heparin (1000 u/kg) and blood removed from the
right carotid artery by a slowly revolving Watson
Marlow MHRE pump. Part of this flow passed
through a cannulating flow probe (Statham, 2.00 mm
lumen) and was carried by silicone tubing through an
incision in the abdominal wall to the catheterized left
renal artery. Renal artery pressure (RAP) was
measured at the tip of this catheter through a fine tube.
The remaining flow was shunted through a Starling
resistance to a femoral vein. Using compressed air,
with a controllable leak, the pressure in the Starling
resistance box and so the mean perfusion pressure of
the kidney could be controlled, while the pulse
pressure remained about 25 mmHg. With this system
Introduction
The mechanism of renal blood flow autoregulation has
escaped elucidation despite many attempts to
implicate such factors as plasma skimming (Kinter &
F'appenheimer, 1956), myogenic responses (Waugh,
1958) and tissue pressure (Hinshaw, Ballus, Day &
Carlson, 1959). A capillaron model has also been
proposed (Murao & Rodbard, 1976) but fails to
predict why there is an upper limit to autoregulation.
Herbaczynska-Cedro & Vane (1973), using pump-
perfused kidneys, demonstrated the abolition of
autoregulation and output of prostaglandin-like
substances by indomethacin, implying prostaglandin E
as a mediator of autoregulation. This was
subsequently challenged. Owen, Ehrhart, Weidner,
Haddy & Scott (1974) failed to abolish autoregulation
in the naturally perfused kidney using indomethacin.
Venuto, O'Dorisio, Ferris & Stein (1975) and
Anderson, Taher, Cronin, McDonald & Schrier
(1975) also failed to abolish autoregulation using
meclofenamate as well as indomethacin.
This discrepancy has been assigned to a
methodological difference, namely the large resting
resistance to flow seen in the pump-perfused kidney
(Venuto et al., 1975; Anderson et al., 1975). We re¬
examined the role of prostaglandins of the E and F
series in the pump-perfused canine kidney using
meclofenamate to inhibit synthesis, and radio¬
immunoassay to estimate renal venous concentrations
of both prostaglandins.
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Figure 1 This figure shows the individual results of
one experiment (expt. 7) before (®) and after (O)
meclofenamate. RBF = renal blood flow; RAP = renal
artery pressure. The lines through the points were
obtained from the cubic expression of each set of
points; y 24.9 ^ 0.040(x-141) + 5.26(x-141P for
control and y = 1 8.5 + 0.037(x - 1 37) +
6.46(x -137)3 for the meclofenamate curve.
the kidney could be perfused at a range of pressures
while the pump ran at a constant slow speed, thus
preventing damage to the blood at high pump speeds.
All pressures were measured with Consolidated
Electrodynamic L223 transducers and the
electronically avcraged.pressures and renal blood flow
signals were recorded on light-sensitive paper
(Honeywell, Visicorder 2206). Pressure flow curves
were obtained by varying RAP every 5 min, since
autoregulation was complete within 3 minutes. After a
control curve was obtained, meclofenamate
(10 mg/kg, i.v.) dissolved in 10 ml of 0.9% saline was
injected and after 15 to 20 min another pressure flow
curve was recorded.
Samples of renal venous blood (10 ml) were
removed at 50. 100, 150 and 200 mmHg during the
determination of the control pressure flow curve and
at 100 mmHg after meclofenamate in 4 experiments.
The samples were collected in ice cold centrifuge tubes
and spun at 4°C for 25 min at 15,000g. The
haematocrit of each sample was noted for estimation
of renal plasma flow and so prostaglandin secretion
rate. The plasma was stored in a freezer for less than 3
weeks before the assay. The plasma was acidified and
the prostaglandins extracted and purified by silicic
acid column chromatography before radio¬
immunoassay.
Prostaglandin antibody was raised in rabbits with
prostaglandin E, conjugated to thyroglobulin by
means of the carbodiimide reaction. The antibody
exhibited a cross-reaction of 100% with prostaglandin
Ej, 2% with prostaglandin A and B groups and 5%
with 13, 14 dihydro-15-keto prostaglandin E2 and was
used at a final concentration of 1/2,000. The
sensitivity was 30 pg/tube (60pg/ml of sample), with
an intra-assay precision of about 15%.
Prostaglandin F was measured by means of the
antibody raised in rabbits to prostaglandin F2a bovine
serum albumin conjugate (Dighe, Emslie, Henderson,
Rutherford & Simon, 1975). The antibody showed a
cross-reaction of 100% with prostaglandin Fla, 2.6%
with Fm and 2% with D2. The other prostaglandin
groups and metabolites cross-reacted less than 1%.
The antibody was used at a final dilution of 1/35,000
and the sensitivity was 45 pg/tube (90 pg/ml of
sample), with an intra-assay precision of about 15%.
Recovery of both prostaglandins was about 60% and
the reported levels were corrected for recovery.
The pressure flow curves were plotted for each
individual experiment after fitting the data by
computer to a cubic expression, which describes the
general shape of the autoregulation curve:
y = p + q(x-m) + r(x - m)3
where p is the flow during autoregulation (point of
inflexion), m is the pressure at this point, q is the slope
of the plateau part of the autoregulation curve, r is a
constant, x is the pressure at any point and y is the
flow at any point.
Figure 1 demonstrates the results of one experiment
(expt. 7) to which the cubic expression has been fitted
by the computer using the method of least squares.
A straight regression line was also fitted to the
experimental points. In I he absence of autoregulation,
the plateau gradient (q) would approximate to the
regression coefficient (ft) such that q//J would tend to
unity. Values of q//j less than one or even negative
were taken as objective evidence for autoregulation.
Values are expressed as means + s.e. and the results
were analysed by Student's 1 test; probabilities less
than 5% were accepted as being statistically
significant.
Results
Mean systolic pressure (101 ±5 mmHg) was well
maintained throughout each experiment. Two
experiments showed no autoregulation and a third lost
autoregulation before completion of the control
period. In the remaining 7 experiments autoregulation
was obtained. Mean autoregulation flow was
54+13 ml/min (n = l) and meclofenamate (10 nig/kg,
i.v.) reduced it to 26 + 6 ml/min (n=6, P<0.05).
Autoregulation was lost in one experiment after
meclofenamate. The mean autoregulation flow
corrected for kidney weight was 1.6 + 0.4 ml/min per g
kidney, which is about 30% lower than that reported
by Ono, Kokubun & Hashimoto (1974).
Midpoint autoregulation pressure (m) did not
change after meclofenamate, 133 ±5 mmHg before
and 144+ 10 mmHg after. The ratio q//f was always
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less than unity before and after meclofenamate (except
in one experiment where autoregulation was lost after
meclofenamate), indicating preservation of autoregula¬
tion. See Table 1 for the haemodynamic data.
There was a tendency for renal venous prosta¬
glandin E concentrations to rise and calculated
secretion rates (the product of the concentrations and
their respective renal plasma flows) to fall as RAP was
reduced. Using absolute values no significance could
be demonstrated due to the large variation in values
between experiments (Table 2). By expressing the
values at 50. 100 and 150 mmHg as ratios of those at
200 mmHg, a statistically significant rise in concentra¬
tion of prostaglandin E was seen at the lowest pressure
of 50 mmHg (P<0.05) and the calculated secretion
rate fell (P < 0.01).
Prostaglandin F concentrations expressed in a
similar manner also rose as pressure fell, reaching
statistical significance at the lowest pressure
(P<0.05). However, prostaglandin F secretion did not
change.
Meclofenamate (lOmg/kg) produced a significant
Table 1 Renal haemodynamics before and after meclofenamate
Experiment
A-control values; B-values after meclofenamate. m = autoregulation midpoint pressure (mmHg); q=slope of
autoregulation point of curve; fi = linear regression coefficient; p is the autoregulation flow (ml/min); q//3 is an
index of autoregulation. In the absence of autoregulation this value tends to unity.
In expt. 6 autoregulation was lost after meclofenamate and the pressure-flow curve becoming virtually
rectilinear. The derived parameters except /5 have little meaning.
Table 2 Prostaglandin E (PGE) and prostaglandin F (PGF) renal venous plasma concentrations and
calculated secretion rates at different renal artery pressures (RAP).
PGE secretion ratePGE concentration
PAP
(mmHg) ng/min ratiosratios
PGF secretion ratePGF concentration
ng/min ratiosratios
Absolute values are given and ratios relative to those values at 200 mmHg. n is the number of observations,
* P< 0.05 tP<0.01
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fall in the calculated secretion rate of prostaglandin E,
at a perfusion pressure of 150mmHg, from
15.65 +4.43 ng/min (4 = 8) to 3.61 ±0.61 ng/min
(//= 8. P< 0.05). Renal venous plasma concentration
also fell, from 315 ±58 pg/ml to 178 ±26 pg/ml
(P <0.05). Prostaglandin F showed a similar response,
with a fall in the secretion rate from
18.93 ± 5.44 ng/min (4=7) to 2.73 ± 0.27 ng/min
(« = 7, P<0.01) and in concentration from
3 14 ±57 pg/ml to 134 ±23 pg/ml (/»< 0.01).
Discussion
Renal blood flow in the anaesthetized dog is dependent
on prostaglandin synthesis, particularly of prosta¬
glandin E2 (Lonigro, Itskovitz, Crowshaw & McGiff,
1973). Infusion of the prostaglandin E and A series
into the canine renal artery increases renal blood flow
(Fiilgraff, Brandenbusch & Heintze, 1974;
Tannenbaum, Splawinskii, Oates & Nies, 1975).
Arachidonic acid also elevates flow and prostaglandin
synthesis inhibition prevents this (Tannenbaum et al.,
1975).
Renal prostaglandins also appear to be involved in
intrarenal blood flow distribution in the dog (Itskovitz,
Stemper, Pacholczyk & McGiff, 1973; Chang,
Splawinskii, Oates & Nies, 1975) and in the rabbit
(Larsson & A„nggard. 1974).
Acute renal ischaemia increases prostaglandin E-
like material present in the renal vein (McGiff,
Crowshaw, Terragno. Lonigro, Strand, Williamson,
Lee & Ng, 1970). Herbaczynska-Cedro & Vane
(1973) confirmed this and showed that indomethacin
prevented this rise in concentration and also prevented
autoregulation. This latter study implied that prosta¬
glandin E was released in response to a lowered RAP
and that this mediated autoregulation.
Beckman & Zehr (1975), using radioimmuno¬
assay, showed that renal venous prostaglandin E con¬
centration rose when renal blood flow was reduced,
but this was due to a dilution effect. A 50% reduction
in flow resulted in a rise in concentration but less than
double the control concentration, which must be
interpreted as a fall in secretion rate.
In calculating secretion rate, it is assumed that the
arterial prostaglandins presented to the kidney are
removed in passage (Aiken & Vane, 1973) so that all
the renal venous prostaglandins can be assumed to
have been newly synthesized by the kidney. It is
possible that the intrarenal metabolism of prosta¬
glandins is flow-dependent, decreasing in efficiency as
the How increases.
In the naturally perfused kidney, prostaglandin
synthetase inhibitors do not abolish renal blood flow
autoregulation (Owen el al., 1974; Venuto et al.,
1975; Anderson et al., 1975). The latter two groups
suggest that the large resting resistance seen in the
pump-perfused kidney (Herbaczynska-Cedro & Vane,
1973) may lead to prostaglandin-dependent auto¬
regulation. This cannot be the case since despite
inhibition of prostaglandin synthesis, 6 out of 7 of our
experiments still showed autoregulation. Prostaglandin
E secretion was reduced by about 70%, in agreement
with Venuto et al. (1975). It is possible that although
secretion rate was greatly reduced, the smaller
reduction in concentration (due to the concomitant fall
in flow) was not enough to abolish autoregulation. It is
possible that intrarenal blood prostaglandin con¬
centration rather than secretion rate per se is
important in determining intrarenal haemodynamics.
In the conscious dog, indomethacin (2 mg/kg) did
not affect blood pressure, renal blood flow or
intrarenal blood flow distribution (Zins, 1975) and
meclofenamate and the competitive synthetase
inhibitor Ro 20=5720 (1 mg/kg) did not alter blood
pressure or renal blood flow (Kirschenbaum & Stein,
1976). However, in these studies, inhibition was not
examined.
Renal blood flow and intrarenal haemodynamics
may be dependent on prostaglandin synthesis in the
anaesthetized dog due to the elevated prostaglandin E
concentrations. In 7 conscious dogs we have obtained
resting renal venous plasma concentrations of prosta¬
glandin E of 191 ±25 pg/ml (4=10), levels
significantly lower than those reported in the
anaesthetized dogs at a pressure of lOOmmllg,
361 ±63 pg/ml («=10, F<0.05). Levels may be
higher in the anaesthetized animal for several reasons.
The high resting resistance in the pump-perfused
kidney will lower flow and so raise concentrations
through a diluting mechanism. Angiotensin is released
during barbiturate anaesthesia and this lowers renal
blood flow (Burger, Hopkins, Tuiloch & Hollenburg,
1976) and will also cause a direct release of prosta¬
glandins (McGiff, Crowshaw, Terragno & Lonigro,
1970).
The mere introduction of the superfusion bioassay
system as used by Herbaczynska-Cedro & Vane
(1973) has been reported to elevate arterial and renal
venous prostaglandin E, possibly due to kiniri
formation (Satch & Zimmerman, 1976). It is possible
that foreign surfaces in general, such as those of the
pump circuit tubing, may have a similar effect.
In conclusion, renal prostaglandins do not appear
to mediate autoregulation of renal blood flow in the
pump-perfused kidney, but may play a role in
determining absolute blood flow, at least in the
anaesthetized dog.
We would like to thank Mr P.H. Whelpdale for his excellent
technical assistance and Dr R. F.kon for his statistical advice
and help. GAV.S. is an MRC scholar.
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The potentiation of exogenous
noradrenaline by prostaglandins F2a
C2 and D2 on the canine saphenous
vein
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Kadowitz, Sweet & Brody (1971) have shown that
prostaglandin F2a (PGF^ potentiates the response of
venous smooth muscle to exogenous noradrenaline
(NA). PGD2 acts similarly to PGFj,, on several
preparations (Horton & Jones, 1974) whilst PGC2 has
similar actions to PGE2 (Jones, Kane & Ungar, 1974).
Experiments are reported here which compare the
potencies of PGF2n, PGD2 and PGC2 on a single
preparation.
The method used was a modification of that des¬
cribed by Webb-Peploe & Shepherd (1968) and was
used to determine the venous response to exogenous
NA before and during infusion of the various PGs.
Both lateral saphenous veins were cannulated at the
ankle and perfused separately, one serving as a control
for the other. NA was injected proximal to the pump
and once a dose dependent relationship was obtained,
the PG infusion was commenced.
PGF2q (1 pg/min) caused a significant potentiation
of the response and the calculated potency ratio (R)
from the pooled results of three preparations was 6.
PGD, (1 pg/min) was not as potent (R=3, from six
preparations) and PGC2 (1 pg/min) was the least
potent (R = 2, from three preparations). Using linear
regression analysis, the results during PG infusion
(1 pg/min) were significantly different from control
.—) - t . . f
(P< 0.05). In the two preparations, PGF2a (0.1 pg/min)
was found to potentiate the response (R= 2). However,
at 5 pg/min there were considerable baseline changes
and no satisfactory tests were performed. At 5 pg/min
PGC2 caused similar baseline changes. Up to
10 pg/min, PGD, was apparently no more potent than
at 1 pg/min and no baseline shift occurred.
The results with PGF2a are largely in agreement
with those of Kadowitz et al. (1971) and a similar
potency ratio for PGF2a (1 pg/min) has been
obtained. We have found PGD2 to be considerably
less potent than PGF2a, whereas it is up to 60 times
more potent, than PGF2„ as a direct vasoconstrictor
in the sheep (Jones, 1975). PGC2 which from our
results is only weakly active in potentiating the effects
ofNA, is in contrast a potent dilator of both resistance
and capacitance vessels in the dog (Jones, Kane &
Ungar, 1974).
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